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ABSTRACT
The prognosis for patients with lung cancer remains extremely poor. Newer,
more effective treatment regimens are required. In this thesis, the
effectiveness of combining human recombinant interferon alpha with various
established cytotoxic agents was assessed in laboratory models of human
lung cancer and a clinical study. The majority of the experimental work
was performed on a series of human bronchial carcinoma xenografts
established in immune deprived CBA mice. Interferon alone had no cytotoxic
effect but appeared to potentiate the activity of various anti-cancer
agents in non-small cell tumours. No such effect was seen in two small
cell xenografts. Further studies suggested that the dosing schedules of
each agent in the combination was important in producing positive effects.
The exact mechanisms by which interferon may interact with cytotoxic drugs
remains unexplained. It was shown that the results obtained in the
xenograft model were not mediated through increased toxicity to the host or
by modulation of cell cycle distribution within the tumour cells.
Assessment of interferon/drug combinations was also performed using in „
vitro models of lung cancer. Significant synergistic interactions were not
demonstrated. A pilot clinical study investigating the potential of
combined treatment with interferon and Cisplatinum was performed in a group
of patients with non-small cell lung cancer. The toxicity of the treatment
was predictable and an encouraging response rate was seen.
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SECTION I - BACKGROUND INFORMATION
Chapter 1
CURRENT MANAGEMENT OF LUNG CANCER
1.1 Introduction
In the Western World lung cancer remains the commonest cause of
death from malignant disease in men (Mould 1983). It is only second
to breast cancer in this respect in women and the incidence of the
disease in the female population has increased at an alarming rate in
England and Wales in the last two decades (OPCS 1982). The prognosis
of patients with lung cancer remains extremely poor. Until recently
it was felt that surgical resection offered the only curative
treatment. However it is now recognised that the vast majority of
patients with lung cancer have generalised disease at presentation.
Radiotherapy is now widely used for palliative treatment in
symptomatic patients considered unsuitable for curative surgery and
recently intensive treatment with combination chemotherapy has
improved the survival of patients with small cell tumours (Smyth
1986). Despite these encouraging results, long lasting, disease free
survival in a significant number of patients has not been achieved
and the cytotoxic agents used are capable of producing considerable
toxicity. Clearly new regimes and particularly more effective agents
are needed to exert a substantial influence on the natural history of
the disease.
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1.2 Surgical Management of Bronchial Carcinoma
Although surgical resection currently offers the best hope of
cure in patients with non-small cell lung cancer (NSCLC) only a small
proportion (15-20%) of patients presenting with this disease are
suitable candidates for operation. In the majority of patients
clinical assessment and routine investigations will reveal evidence
of spread of tumour from the primary site and in some, significant
impairment of cardio-respiratory function precludes surgical
exploration.
The results of many large series of patients undergoing
successful resection suggest that approximately 25-35% will survive
five years, 15% will live for ten years and 5% will be alive at
twenty years (Belcher 1965, Paul son 1976, Mountain 1977 , Wilkins
1978, Abbey Smith 1981, Bates 1981).
Improved post operative survival appears to be closely related
to the stage of disease at operation, with involvement of mediastinal
lymph nodes carrying a particularly poor prognosis (Mountain 1974\
In a series of 3919 patients from the Mayo Clinic (Williams 1981),
16% were considered to have post surgical stage I disease. The five
year survival for these patients was 69%. Higgins (1979) showed that
the improvement in five year survival from 28% to 45% in two large
Veterans Administration surgical trials was accounted for entirely by
a higher proportion of more favourable TNM staged patients in the
second study.
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The role of surgery in the management of small cell lung cancer
(SCLC) remains controversial. Most surgeons now agree that in this
disease the incidence of dissemination at presentation is so high
that in virtually all cases the rational therapeutic approach is the
use of systemic chemotherapy (Mountain 1974, Osterlind 1985). The
overall survival figures for surgery as primary treatment of small
cell lung cancer are very poor with most centres reporting few
patients alive after two years (Mountain 1977, Fox 1973, Wilkins
1978).
The rationale for surgical treatment of SCLC appears especially
dubious as even the best centres report an operative mortality rate
of 4-12% depending on whether a pneumonectomy or lobectomy is
undertaken. However when a diagnosis of small cell cancer is made
only after resection and glands are not involved, then prognosis
compares favourably with other histological types (Shields 1975,
Wright 1981).
1.3 Radiotherapy in the Management of Bronchial Carcinoma
The effectiveness of radiotherapy in the management of lung
cancer depends on tumour histology, size and dissemination. SCLC is
highly radiosensitive although as stated above is usually a
generalised disease at presentation making curative treatment with
radiation impossible in virtually all cases.
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In seemingly 'operable' patients with small cell tumours,
radical radiotherapy has been shown to be more effective in producing
long term survivors than surgery (Fox 1973). However most workers
would now agree that for the majority of patients with this disease
the treatment of choice is combination chemotherapy.
Non-small cell lung cancer is less radiosensitive than SCLC and
the results of radical radiotherapy compare poorly with surgical
resection in operable patients. In a randomised comparison of these
treatments in 58 operable patients (Morrison 1963) a marked survival
advantage was seen in the surgically treated group (23% against 7%
four year survival) particularly when the histology was squamous
carcinoma. The place for radical radiotherapy in non-small cell
tumours may be confined to Stage I patients in whom there is a
medical contraindication to operation or to patients with Stage II
disease where complete resection has not been achieved (Gregor 1984).
The results of many studies of radical radiation treatment in
inoperable patients suggest that 35-50% will survive one year but
only 5-7% will be alive after five (Deeley 1967, Caldwell 1968, Coy
1980). However of all the studies published, only one (Roswitt 1968)
was conducted in a randomised fashion comparing the effect of
radiation with no therapy. Only a marginally significant effect of
treatment on survival was demonstrated although both the design of
the study and methods of analysis used have been criticised. The
rationale for treating inoperable patients with radical radiotherapy
therefore is not supported by convincing data and more carefully
controlled studies using modern radiation techniques are required.
-5-
This whole subject is well covered in an excellent critical review
by Kjaer (1982).
No advantage in terms of patient survival has been demonstrated
in combining radiation therapy with either chemotherapy (Gregor 1984)
or surgery (Kjaer 1982) although there may be a place for pre¬
operative therapy in patients with superior sulcus (Pancoast) tumours
(Paulson 1975). Perhaps the main indication for radiotherapy in lung
cancer nowadays lies in its ability to palliate symptoms effectively.
Haemoptysis, thoracic and bone pain, stridor and the effects of
superior vena caval obstruction in general respond well to radiation
therapy (Slawson 1979).
The exact place of radiation treatment in lung cancer is still
uncertain. Until more carefully designed randomised studies of
radical treatment are forthcoming it may be reasonable to reserve the
use of radiotherapy for patients medically unfit for curative surgery
and for palliation in symptomatic cases.
1.4 Chemotherapy in Bronchial Carcinoma
Autopsy studies indicate that all histological types of lung
cancer can metastasise widely. This is especially true of small
cell tumours where in one series (Matthews 1976) only 4% of cases had
disease confined to the thorax. The same author (1973) performed
post mortems on 202 patients dying within one month of an apparently
"curative" resection from causes unrelated to lung cancer.
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Persistent disease was found in a third of patients with squamous
tumours, 16% of large cell cases and 40% of adenocarcinomas. Almost
70% of patients with small cell tumours had residual disease with 92%
of these having distant metastases.
These figures may explain why with the current diagnostic
techniques, local therapy i.e. "curative" surgery or radical
radiotherapy will not eradicate this disease in the majority of
cases. They provide further evidence to support the rationale of
using systemic therapy especially in small cell cancers. These
tumours are sensitive to many anti-cancer agents and most workers now
agree that combination chemotherapy is the appropriate first line
treatment. Non-small cell tumours are less chemosensitive and the
use of drugs in this heterogeneous group is controversial and will be
considered separately. It is for this reason that the importance of
establishing an accurate histological diagnosis even in patients with
widespread disease cannot be overstated.
1.4a Non-Small Cell Lung Cancer
Approximately 60% of patients developing NSCLC have evidence of
metastases at presentation (Souhami 1985) and in the majority of the
remaining patients surgery or radical radiotherapy will fail to
eradicate the disease. Theoretically therefore it would seem
appropriate to treat the majority of NSCLC patients with systemic
chemotherapy. Unfortunately the relative insensitivitv of these
tumours to the' currently available cytotoxic agents makes this form
of management unsatisfactory especially as the toxicity of these
drugs may be considerable.
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The use of differing response criteria in small uncontrolled
series of patients with varying histological types and prognosis has
made the interpretation of drug activity in this disease difficult.
Also, all results need to be interpreted in the knowledge that a
small proportion of patients will survive for more than two years
without treatment. Despite these difficulties, which can only be
overcome by undertaking randomised comparisons between treated and
untreated patients (Souhami 1985), many drugs have been shown to have
activity in this disease.
(i) Single Agent Activity
Early trials (Selawry 1973, 1974) reported encouraging response
rates to the available agents. More recently the results appear less
optimistic perhaps due to the inclusion of heavily pre-treated
patients. Of the many drugs assessed in this disease (Table 1.1)
four deserve mention.
Ifosfamide, an alkylating agent related to cyclophosphamide,
gave response rates of between 24% and 32% in three separate studies
(Morgan 1983, Costanzi 1982, Harrison 1982) with the median survival
in responding patients in one (Costanzi 1982) being 10 months.
Cis-platinum has been given in various schedules with the two
largest studies (DeJager 1980, Vogl 1982) reporting response rates of
25% and 32%.
Vindesine has been assessed in nine different studies with
response rates varying from 6% (Vogelzang 1982) to 31% (Furnas 1982)
despite almost identical dosage regimes.
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(TRIALS >3, PATIENTS >100)
(AFTER BAKOWSKI 1983)
TABLE 1.1 - SINGLE AGENT ACTIVITY IN NSCLC
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Mitomycin C highlights the problems of assessing agents in this
heterogeneous group of tumours. Response rates observed have ranged
from 9% in an early study (Whittington 1970) to an impressive 40% in
a small group of patients with squamous histology (Koons 1978).
One other single agent study is worthy of note in that it
compared response rates and survival after two different doses of a
drug (methotrexate) against placebo (Selawry 1977). Objective
response was dose related with rates of 21% for 'high' dose, 11% for
low dose, and 6% for placebo. Median survival was prolonged in
responders compared with non responders (34 weeks versus 11 for high
dose, 52 weeks versus 13 for low dose). The median survival in the
placebo group (11 weeks) was similar to that of non responders in
both treatment groups. Overall activity of single agents in NSCLC is
shown in table 1.1
(ii) Combination Chemotherapy
Despite little evidence of significant single agent activity in
this disease many combinations of cytotoxic drugs have been triec.
Many of the shortcomings of the single agent studies noted above also
apply to drugs given in combination. The various response rates af
drug regimes containing one to four or more agents have been well
summarised by Souhami (1984, 1985). In general there appears to be a
tendency for combination therapy to produce higher response rates in
squamous and adenocarcinoma subtypes but this may not hold for large
cell tumours (Table 1.2). Overall response rates for drugs in
combination are not much higher than with the best single agents and
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in some studies (e.g. Klastersky 1983) the addition of a third agent
only adds to the overall toxicity.
Gralla (1981) studied the combination of vindesine and two
2 2different does of cis-platinum (60mg/m and 120mg/m ) in a group of
81 patients with predominantly adenocarcinoma histology. Response
rates for each regime were similar (46% and 40% with 10% complete
responses) but the median duration of response (12 months versus 5.5
months) and median survival in responders (21.7 months versus 10
months) was prolonged in the high dose platinum group. These results
are encouraging although the toxicity of the high dose regime was
substantial. Other workers (Hansen 1976, Eagan 1979, Roberts 1980)
have also noted the relative effectiveness of combination
chemotherapy in adenocarcinoma.
Only one study of combination chemotherapy has compared
treatment with an untreated control group (Cormier 1982) and few make
a comparison with single agent therapy. Many authors unjustifiably
point to increased survival in responding patients compared with
non-responders as evidence of efficacy. There is no substitute for
an appropriate untreated control group in any assessment of therapy
in this disease as it may be possible that responders to therapy
would have survived as long without treatment.
In the one study where combination chemotherapy (methotrexate,
adriamycin, cyclophosphamide and CCNU) was compared in a prospective
randomised fashion to placebo, the benefits of treatment were obvious
(Cormier 1982). 35% of the treated group responded with no responses
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TABLE 1.2 Mean percentage response rate (with range) to various drug
combinations (1 - 4+ drugs) in the three main histological subtypes
of non-small cell lung cancer. (From Souhami 1984)
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seen in the placebo group. Median survival for treated patients was
30.5 weeks compared to 8.5 weeks for untreated.
Combination chemotherapy is rarely used as palliative treatment
in NSCLC as most effective regimes have concomitant toxicity.
However the instillation of cytotoxic agents into the pleural space
in patients with recurrent malignant effusions may prove useful
palliative treatment.
In summary at the.present time, the use of chemotherapy in
patients with non-small cell lung cancer should be confined to
carefully designed research studies in an attempt to find newer, more
effective treatment regimes.
1.4b Small Cell Lung Cancer
The greatest advance in the management of bronchial carcinoma in
recent years has been the improved survival in patients with small
cell tumours treated with systemic combination chemotherapy. SCLC
differs from the other types of lung cancer in the propensity for
rapid growth and early dissemination. The TMN (Tumour, Nodes,
Metastases) staging system which is widely used for most forms of
cancer has been shown to have little relevance in the management of
SCLC patients in whom the disease is usually disseminated at
presentation (Mountain 1974). This led to the development of a
specific staging system of "limited" (i.e. confined to one hemithorax
including ipsilateral scalene nodes) and "extensive" disease. The
median survival of placebo treated patients with limited disease has
been shown to be 3 months, while patients with extensive disease have
a median survival of 6 weeks (Zelen 1973). These figures emphasise
the aggressive malignant nature of this disease.
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In 1969 Green and colleagues showed that the lifespan of
patients with extensive SCLC could be doubled with three courses of
treatment with cyclophosphamide compared to placebo. Since then the
activity of a variety of single agents in SCLC has been established
(Table 1.3). Objective response rates of 30-40% are seen with many
drugs but these responses are in general short lived with complete
remissions being extremely unusual. In an attempt to improve on
these results combination chemotherapy was tried with a marked
improvement in the response rates and survival compared with single
agent treatment (Alberto 1976, Edmonson 1976, Lowenbraun 1979).
Over the past 10 to 15 years a large number of patients with
SCLC have undergone combination chemotherapy with many different
agents in numerous studies. A number of facts have been clearly
established:
(i) Using combination chemotherapy involving principally agents
listed in Table 1.3, an objective response rate can be obtained in
approximately 75% of patients in whom 15-25% will achieve a complete
remission.
(ii) Survival in complete responders is significantly longer than
that observed in patients with a partial response.
(iii) Patients with limited disease have higher complete response
rates and more prolonged median survival (e.g. 60% versus 25%, 51

























TABLE 1.3 Objective response to single agent chemotherapy in small
cell bronchogenic carcinoma (from Hansen 1980)
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(iv) The survival of extensive disease patients who achieve a
complete response is comparable to that of limited disease patients
who achieve a complete response.
(v) Even with these encouraging responses 50% of patients with
limited disease die within the first 12 months after diagnosis and
80-90% succumb within the first two years (Comis 1982). Many
patients who respond to treatment and are disease free for two years,
remain disease free and may even be considered cured (Ginsberg 1979).
1.5 Combined Radiotherapy and Chemotherapy in SCLC
The exact place of radiotherapy in the initial induction
treatment remains uncertain. Most studies include radiation therapy
to the primary tumour and to draining lymph nodes between courses of
combination chemotherapy - so called "sandwich radiotherapy". The
evidence that adding radiation therapy to standard chemotherapy is
beneficial is supported by only one study (Oldham 1981) where the
complete response rate was higher with a combined modality approach.
In four studies (Fox 1980, Smyth 1980, Stevens 1979, Williams 1977)
no such benefit was seen and indeed Hansen (1979) reported a
significant shortening of median survival after chemotherapy from 14
to 11 months with the addition of radiotherapy.
The optimum sequence and timing of radiotherapy in relation to
chemotherapy has not been established nor has the precise dose of
radiation required to gain the maximum benefit without significant
toxicity. Simultaneous treatment with drugs and radiotherapy may be
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more effective in producing a remission than "sandwich" therapy
(Comis 1982) but its toxicity appears unacceptable especially if
adriamycin is included in the drug regime (Feld 1981).
Prophylactic whole brain irradiation has been shown to reduce
the incidence of overt cerebral metastases but has not been shown to
have any positive effect on survival (Maurer 1980).
Despite these unresolved questions which can only be answered by
well planned clinical studies, radiotherapy continues to be included
in most treatment regimes. It may be significant that virtually all
the long term (more than 2 year) survivors in SCLC underwent combined
modality therapy.
1.6 Methods of optimising chemotherapy in SCLC
Much of the clinical research performed in SCLC in the last few
years has been aimed towards increasing the proportion of patients
achieving a complete response and to improve the duration of such
responses, as it is these patients who stand the best chance of long
term survival.
(a) Intensification of treatment
In 1977 Cohen and colleagues using a well studied induction
regime of CCNU, cyclophosphamide (CY) and methotrexate (MTX) showed
that doubling the dosages of CCNU and CY and increasing the dose of
MTX by half, doubled the objective response (45% to 96%) and median
survival (20 to 42 weeks). Smyth (1981) improved on the complete
2
response rate by increasing the dose of MTX from 15 mg/m orally to
2 .... ...
200 mg/m as an l.v. infusion with folmic acid rescue.
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Many other workers have since tried high dose induction therapy
with a variety of drug combinations usually combined with sandwich
radiotherapy. Impressive complete response rates of 70-80% in
limited disease and up to 50% in extensive disease have been
achieved. However the impact on long term survival has been
extremely disappointing and many treatment regimes have been
associated with significant toxicity.
Late intensification therapy has been tried in an attempt to
prolong complete remissions. High dose drug treatment, often with
total body irradiation and autologous bone marrow transplantation,
has been given to patients achieving a complete remission with
standard induction therapy (Stewart 1983). Unfortunately this
aggressive treatment has failed to improve on the survival figures
achieved with standard induction chemotherapy. Indeed recently the
whole rationale for giving maintenance chemotherapy has been
questioned and further trials are required to determine the optimum
intensity and duration of treatment in SCLC.
(b) Non-Cross Resistant Drug Regimes
In an attempt to overcome the development of drug resistance
after induction therapy, many centres have evaluated mutually
non-cross resistant chemotherapy regimes. Cohen (1977) improved
further on the results with MTX, CY and CCNU mentioned above by
alternating courses of vincristine, adriamycin and procarbazine. The
complete response rate obtained using alternating chemotherapy
increased from 30% to 56% and median survival from 42 to 61 weeks.
Many other workers (e.g. Aroney 1982, Dombernowsky 1979) have also
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demonstrated that a second non-cross resistant drug combination can
be shown to have some effect. However, they have failed to produce
any real benefit in terms of patient survival.
1.7 Treatment of SCLC - the future
As stated above, in the last decade the outlook for patients
presenting with SCLC has improved greatly. The use of aggressive
combination chemotherapy has increased the median survival of
responding patients with virtually all responses being associated
with significant palliation. A small though important minority of
patients are now alive and disease free at two years with a chance of
long term survival. The challenge for the future is clearly to
increase the percentage of patients achieving these long remissions.
What is the way forward?
In clinical terms, it would seem important to continue to try to
optimise chemotherapy by giving the most active drugs available in
regimes which maximise cytotoxicity to the tumour without creating
intolerable side effects. In the long run however it seems likely
that major therapeutic advances will not be made unless more
effective anti-cancer agents become available.
The chances of developing such agents have been greatly improved
by the fact that many investigators are now able to grow human
bronchial carcinomas either using special tissue culture techniques
or in immunodeficient mice. This has greatly facilitated the study
of the biological, immunulogical and cytogenetic characteristics of
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this disease (Smyth 1985) thus allowing the development of more
novel therapeutic strategies such as growth factor antagonists,
immunomodulators and techniques involving monoclonal antibodies.
The efficacy of any new treatment regime can be rapidly assessed
in the laboratory using either an in-vitro assay or xenografts
established in immunodeficient rodents. It is to be hoped that over
the next few years a greater understanding of the biology of the
disease can be translated into encouraging therapeutic advances for
the patient diagnosed as suffering from this terrible condition.
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CHAPTER 2
LABORATORY ASSESSMENT OF ANTI CANCER AGENTS
2.1 Introduction
One of the major problems encountered by clinicians who treat
cancer patients with chemotherapy is the fact that tumours which
according to histological characteristics are identical nevertheless
are highly individualistic in their sensitivity to anti-cancer
agents. At present the decision to use or not to use a particular
drug in a particular patient is based on the results of previous
clinical trials in patients with the same type of tumour. Thus the
knowledge that a particular drug has a low level of activity in a
specific tumour may prevent the use of that drug in a few patients
who might greatly benefit from it.
The success of the in vitro testing of the sensitivity of
bacteria to antibiotics led to much interest in the development of a
similar system where the sensitivity of human tumours to a given
cytotoxic agent could be rapidly assessed in the laboratory. Clearly
such a test would have two important applications. Firstly, it would
be invaluable in the screening of new compounds or drug regimes that
have potential use in treating cancer patients. Secondly, with
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pretreatment testing of a patient's tumour to a wide range of
chemotherapeutic agents it might be possible to 'individualise' drug
regimes. This would allow treatment with agents known to be active
in that particular tumour and prevent the use of inactive drugs with
their associated toxicity.
Such a test would ideally be simple, cheap, rapid, easily
standardised, statistically acceptable, capable of allowing for
various methods* of drug action and offer reasonable correlations with
effects seen in the patient. Over the past three decades many
different in vitro predictive assays and animal model systems have
been developed (Figure 2.1) but at the present time no single
technique has satisfied the above criteria as a reliable predictive
test for cancer therapy.
Although the tailoring of individual patient therapy using
laboratory systems has not been achieved, there now exist many
different methods of assessing the activity of anti-cancer agents
outwith the patient. Both in vitro and in vivo systems have proved
invaluable in the development of all the currently available
chemotherapeutic agents and these techniques will hopefully
facilitate the evolution of newer, more effective treatment regimes.
2.2 In vitro methods of drug testing
Harrison (1907) and Carre 1 (1912) were the first researchers to
demonstrate that animal cells could be taken from an organism and

















drug effects in vivo
Figure 2.1: Laboratory methods of assessing anti-cancer agents
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thirty years, tissue culture techniques have become extremely
sophisticated and many workers have attempted to evolve systems to
accurately test the activity of cytotoxic drugs in tumour cell
preparation.
The majority of in vitro test systems involve the preparation of
a single cell suspension of tumour cells which are then exposed to a
fixed concentration of the cytotoxic agent being evaluated.
Drug-induced cell damage can then be assessed using a number of
different criteria and the activity of a number of different drugs in
the one tumour cell type can then be compared. Several technical
problems are encountered at all these steps.
2.2(a) Preparation of a single cell suspension
In general terms after surgical resection of a tumour,
homogenates are prepared for drug testing by separation of the
specimen into single cells or by dissection into small fragments. A
single cell suspension may be produced mechanically with scissor-s or
by the action of proteolytic enzymes such as trypsin, dispase or
collagena se.
The viability and yield of cells depends directly on the method
used to prepare the suspension as well as on the histological
structure of the original tumour. Tumours having a dense stromal
element requiring long mechanical processing give rise to cell
suspensions of low viability. A reduced cellular vitality has also
been associated with enzymatic treatment (Hofer 1974) and some
workers (Barranco 1980) have reported a change in sensitivity of
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cells to cytotoxic agents after exposure to trypsin. These problems
may be overcome by using tumour fragments. However the disadvantage
of this method lies in the inherent heterogeneous structure of most
tumours with a marked regional variation in cellular metabolism
observed within one tumour population (Siracky 1979).
2.2(b) Selection of appropriate drug concentration
The effectiveness of most anti-neoplastic agents corresponds
directly to its serum concentration and to the amount of time an
effective serum level can be maintained. For several agents a method
of determining their ideal concentration in vivo remains to be
developed. Numerous factors such as drug activation and catabolism,
varied mechanisms of transport and dissimilar vascular and metabolic
conditions in individual tumours prevent accurate estimation of
'effective' therapeutic drug concentrations in vivo and therefore
makes appropriate drug monitoring in vitro impossible.
Different groups of workers select drug concentrations for
sensitivity testing using various criteria e.g. based on the dose
producing cell death in 50% of cultured cells (ID50), on the
inhibition of growth of known cell lines (e.g. HeLa cells, Wright
1962), by using concentrations which respond to the serum therapeutic
dosage converted to mg/ml of culture media, or merely on an arbitrary
basis.
In most in vitro systems the contact time of the drug being
assessed with the tumour cells is relatively long. Since the
effective dose is calculated from a concentration x time
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equation, the concentration of drug must initally be lower or the
exposure time limited if a 'reasonable' drug exposure is to be
achieved. In any test system it would seem reasonable to utilise
several concentrations of a particular agent when attempting to
define drug sensitivity.
2.2(c) Criteria for cell damage
When tumour cells are exposed to an anti-cancer agent, they do
not exhibit an "all or nothing" reaction and a variety of influences
on several measurable parameters are observed. The in vitro
predictive test systems which have been developed over the past 25
years are in essence several different methods of measuring drug
induced cytotoxicity using a variety of different parameters.
Structural cell damage, viability, inhibition of cellular metabolism
including radioactive precursor incorporation and measurement of
cellular reproduction capacity (colony formation) have all been used
as end points to measure the effectiveness of cytotoxic agents in
vitro. These systems will now be considered.
2.3 Specific Predictive Systems
2.3(a) Morphological assessment of cellular damage
The earliest assessment of the effect of cytotoxic agents in
vitro involved an evaluation of morphological cell damage. Wright
and colleagues (1957) established fresh biopsy specimens as explant
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cultures and then added drugs for 96 hours. Drug effects were
evaluated microscopically by experienced observers and cell damage
scored on a subjective scale. The initial report was encouraging
with a good correlation demonstrated betweeen in-vitro tumour
sensitivity and the subsequent clinical response. However, further
studies by this group (Wright 1962) and others (Yarnell 1964) proved
less encouraging with inconsistent responses from groups of cells
from the same tumour, false positive in-vitro results, a lowish
success rate in establishing biopsies in culture and a major
subjective component involved in assessing drug-induced cell damage.
2.3(b) Measurement of cell viability
In an attempt to render morphological assessment of cytotoxicity
less subjective, other assay systems measuring cell viability have
been developed.
(i) Dye exclusion assays - The ability of viable cells to exclude
supravital stains such as trypan blue, eosin and nigrosin has been
used in assay systems for many years. Unfortunately most authors
conclude that vital dyes are not reliable indicators of drug-induced
cytotoxicity (Roper 1979), with a poor correlation between dye
exclusion and long term reproductive ability (Rupniak 1983). However
a recent report from Weisenthal and colleagues (1983) using a novel
dye exclusion method demonstrated a better in vitro/in vivo
correlation and using this assay, Bosanquet (1983) has shown valid
results in determining the chemosensitivity of patients with chronic
lymphatic leukaemia.
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(ii) Chromium Release Assay - The degree of damage to cell membranes
may be estimated by the release of chromium-51 in a previously
labelled cell. Little experience has been reported with its use as
an assay of chemotherapeutic drug effect. It shares the same
weaknesses as dye exclusion tests in that although loss of cell
membrane integrity may be a relatively early event in cell death, it
is probably not a sensitive indicator of lethal drug-induced damage.
(iii) Loss of adherence - Holmes (1974), studying a small group of
patients, reported an overall clinical correlation of 92% (100% true
+ve, 88% true -ve) with cell kill assessed by loss of monolayer
adherence. The period of in vitro exposure was relatively long (72
hours) and commenced only 24 hours after the cells were placed in
culture. Only cells known to be viable by dye exclusion were used in
the final adherence assay and only 13 patients were available for the
clinical correlation. No other studies of cell adherence assays have
been reported.
2.3(c) Measurement of Inhibition of cellular metabolism
Black (1954) in one of the earliest in vitro assays attempted to
evaluate the response of human tumour cells to a variety of drugs by
investigating inhibition of dehydrogenase activity by reduction of
tetrazolium dyes. Although they demonstrated a positive correlation
between in vitro effects and clinical response in the patient, other
workers have been less enthusiastic, with many showing high (up to
50%) false positive in vitro results (Pi Paoli 1961, Kondo 1971).
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Despite this, reports have appeared recently describing colorimetric
assays suitable for rapid testing of cancer cells with multiple drug
combinations (Cole 1986).
Although fairly reliable at predicting non-response, assays that
measure inhibition of cellular metabolism have not been actively
pursued. Tests that measure changes in oxygen consumption have
proved technically difficult with large variations observed in
results from control cell populations. The other main problems with
these assays are the qualitative nature of the results and the fact
that the metabolism of both malignant and non-malignant cells is
«S*
measured.
2.3(dMeasurement of radioactive precursor incorporation
The measurement of the incorporation of radiolabeled
nucleosides (uridine, deoxyuridine, thymidine) into tumour cell
preparations during in vitro drug exposure has been widely used as an
indirect method of assessing cytotoxicity and remains an active area
of investigation. Bickis (1966) provided the initial model for this
form of assay by incubating slices of fresh human tumours with a
number of anti-cancer drugs in the presence of radioactive tracers.
32
Since then other labels such as p (Yarnell 1964), radioactive
leucine in long term culture (Morgan 1983) and tritiated thymidine or
uridine in short term culture (Volm 1979) have been used.
Although positive correlations between depression of DNA
synthesis in vitro and clinical responses in patients have been
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observed (Mat tern 1982), when compared to other in vitro tests, these
measurements may not give an accurate assessment of cell survival
(Roper 1976, Rupniak 1983). The problems with this assay system
include:-
(i) The lack of incorporation of DNA precursors by tumours with a
long cell cycle time or a large population of non-cycling cells.
(ii) Precursor incorporation into cells may be temporarily stopped
by damage to cells in the isolation process.
(iii) Drug induced changes in nucleotide pools or nucleotide
transport may cause underestimation of DNA synthesis.
(iv) Overestimation of DNA synthesis may arise from increased use of
salvage pathways in the presence of drugs such as 5FU and
methotrexate that affect the de novo pathway.
(v) The inability of the method to distinguish between DNA
synthesis in tumour and non-tumour populations.
Attempts have been made to overcome these problems by using
modified stem cell assays (Friedman 1982) and labelling index
techniques (Livingston 1980) and much interest is still being shown
in this form of assay.
2.3(e) Measurement of Reproductive Capacity (Clonogenic assays)
A major drawback of the systems described so far is the fact
that they measure the effect of drugs on the entire cell population,
which in most cases comprises a mixture of normal and neoplastic
cells. Clearly measurements that include normal cells may give
misleading results but also it has recently become apparent that even
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the population of neoplastic cells in a given tumour is heterogeneous
in its growth characteristics. Cell kinetic studies indicate that in
most cases the bulk of tumour cells turn over slowly, die or
terminally differentiate. Only a small percentage of the total
population is made up of cells capable of repopulating the tumour -
the so called "stem cells". These cells have been well characterised
in bone marrow where they comprise approximately 1% of the total
population (Pike 1970). Thus many of the in vitro assays already
described measure the effect of drugs on cells that will probably not
divide in vivo.
Stem cells at any particular time may be proliferating or
non-proliferating. The large proportion of non-proliferating
potential stem cells includes cells that can be stimulated to divide
in vivo and it has been postulated that these cells may be
responsible for the regrowth of tumours after treatment with
cytostatic drugs. If such a hypothesis is correct then clearly the
best in vitro assay system for predicting response to cytotoxic
agents should selectively measure the effects of drugs on this small
population of stem cells.
In 1971, Park and colleagues devised an in vitro system for
cloning cells from transplantable murine myelomas and showed that the
results obtained for drug assays in vitro mirrored in vivo responses.
This work led to major developments in culturing stem cells from
human tumours using a two layer soft agar system (Hamburger 1977).
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In this assay (figure 2.2), a single cell suspension is prepared
and mixed with culture medium and 0.3% agar (or agarose) at 40° C.
One ml of the mixture is then plated in triplicate in 35mm plastic
Petri dishes over a base layer of 0.5% agarose in culture medium that
has hardened. Cultures are then incubated at 37° C in a well
humidified atmosphere of 5-10% CO2/90-95% air. Colonies (i.e.
aggregates of 50 cells or more) are usually observed 7-21 days after
plating. The number of colonies that grow is proportional to the
total number of cells plated and thus a quantitative estimate of drug
effects on colony forming cells can be made.
At the same time that Hamburger and Salmon were developing their
clonogenic assay using myeloma cells, Courtenev (1978) reported on a
replenishable soft agar assay for solid tumours, where colonies grow
in low oxygen tension in the presence of rat erythrocytes. Both
systems take advantage of the observation that fibroblasts which
normally 'contaminate' tumour cell cultures do not grow in soft agar.
These two assays are now the most commonly used methods of assessing
the activity of cytotoxic drugs in'vitro;
2.4 Drug testing using the clonogenic assay
2.4(a) Methodology
Since the original description of the clonogenic assay, many
investigators have attempted to grow most types of human cancers in
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Figure 2.2: The clonogenic assays
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been cultured with ovary, melanoma, lung and colon faring best
(Salmon 1981, Von Hoff 1981). However, even in these examples only
50% of tumours tested were capable of producing enough colonies for
drug testing (Mattern 1982). This disappointing value may be
attributable to (i) reduced cell viability during isolation and
preparation of single cell suspensions, (ii) nutritional or hormonal
requirements specific to the tumour of origin, (iii) an expression of
insufficient proliferation of the tumour.
In the standard assay system (Figure 2.2),(Hamburger 1977,
Courteney 1978, Salmon 1981), cells are incubated for varying times
(normally 1 hour) with different concentrations of a specific drug.
Cells are then washed, unless continuous exposure is required, and
plated out in agar. After 2-3 weeks of incubation, plates are
counted and the activity of the drug expressed in terms of the colony
survival in treated plates compared with controls. In most studies a
mean colony count of at least 30 in control plates is required for
the assay to be considered evaluable. In vitro sensitivity at a
specific drug concentration is usually associated with a colony
survival of 30% or less of controls, with colony survival in excess
of 50% considered to indicate resistance (Von Hoff 1981).
2.4(b) Clinical correlations of the clonogenic assav
Salmon and colleagues at the University of Arizona reported the
initial correlations of in vitro chemosensitivity and clinical
response in 176 patients with myeloma, melanoma and ovarian cancer
(Salmon 1983). The true positive rate was 67% and true negative rate
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93%. Many other workers have published similar results in different
tumours and using different assay methods. These results are well
summarised by Carney (1985), who showed that in 715 direct in
vitro/clinical correlations in 11 major studies, the overall true
positive rate was 70% (range 42-92%) and the true negative rate was
92% (range 83-100%).
Can these in vitro correlations be used to improve the
management of patients in the clinic? In a prospective trial, Von
Hoff (1983) treated patients with single agent therapy based on in
vitro assay results. He showed a higher objective response rate
(25%) in patients whose treatement was based on clonogenic assay
results than in those patients treated with the physician's choice of
drug (11%) or where specimens failed to grow in the assay (14%).
However this was not a randomised study and each group was extremely
heterogeneous. In a small study of untreated patients with myeloma
(Purie 1983), median survival was 48.5 months for 8 patients with in
vitro sensitivity to melphalan but only 9 months for 8 patients
resistant to melphalan in vitro.
Although these results appear encouraging, at the present time
it is not feasible to use clonogenic assays to "tailor" chemotherapy
for individual patients. The foremost problem continues to be the
inability of many tumours to grow in the assay, with successful
colony formation being achieved in only 3U-40% in the best centres.
In addition, pharmacological considerations including drug dosages,
activation, duration of exposure and drug/drug interactions pose
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difficulti.es in the clonogenic assay. Other problem areas exist such
as the exact definition of a colony and the criteria used for
defining sensitivity or resistance. A major drawback to using
clonogenic assays as predictive tests has been highlighted by Von
Hoff (1986) who showed a great variation in chemosensitivity between
two tumour specimens from the same patient.
Until these technical problems are overcome, the in vitro tests
of cytotoxicity should be considered as important research tools and
not for widespread clinical application. Perhaps in the fullness of
time they may prove most useful in identifying which drug should not
be given as most studies show a predictive accuracy of in vivo
resistance greater than 90%. However this figure may merely reflect
the relative chemoresistance of most human tumours (Twentvman 1985).
2.5 Animal Tumour Models
Over the past three decades, many workers have attempted to
develop animal models to assess the activity of anti-cancer agents in
vivo. The advantages of such a system over in vitro methods are
clear.
Drug testing in vivo can be performed on solid intact tumours
which have a blood supply integrated with the vascular system of the
host. Tumour disruption to form a suspension of cells can be
avoided. The drug or combination of drugs being assessed can be
administered in a similar manner to their clinical application. They
are transported by normal pathways to the tumours and are subject to
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the same metabolic and pharmacokinetic interactions seen in patients.
The drugs can act through several cell cycles and it is possible to
test compounds which must undergo metabolic activation (e.g.
cyclophosphamide) to be fully active.
It is for these reasons that most workers agree that more
relevant results can be obtained when anti-cancer agents are assessed
using animal models compared with in vitro methods.
2.5(a) Transplantable rodent tumours
The first in vivo systems used for drug testing involved the use
of transplantable rodent tumours which had arisen either
spontaneously or through viral or chemical induction. The L1210
murine leukaemia, P388 leukaemia, B16 melanoma and Lewis lung
carcinoma have been the most widely used murine tumours and formed
the basis of a massive drug development programme set up over 30
years ago at the National Cancer Institute (Carter 1977).
Although the vast majority of anti-cancer agents in current
clinical use were developed using rodent tumour systems, few
similarities exist on a biological or biochemical basis betwen these
tumours and solid human cancers. In an attempt to mimic more closely
the behaviour of human neoplasms, many people have tried to
heterotransplant human tumours into laboratory animals. Initial
attempts using many different species as hosts were unsuccessful.
This led to the development of various techniques to avoid the
immunological rejection of the foreign tumour tissue by the host
animal.
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2.6 Human Tumour Xenografts
2.6(a) Immune-privileged sites
Implantation of human tumours to immune-privileged sites such as
the anterior chamber of the eye, brain, subrenal capsule or cheek
pouch has been successfully attempted (Green 1953). Unfortunately
only limited growth of the xenograft is possible and progressive
growth measurements are difficult. The techniques may prove valuable
for establishing certain tumour types that fail to grow elsewhere or
where therapy specific for that site is being investigated e.g.
retinoblastoma will grow in the anterior chamber of the eye of Swiss
nude mice but not in other species (Gallie 1977). Epstein (1967) has
successfully grown human lymphomas in the brains of certain nude mice
strains. Cobb (1974) found the hamster cheek pouch (+ATS adjuvant
therapy) to be as receptive a host as artificially immune-suppressed
CBA mice. However relatively few chemotherapy studies using these
models have been reported.
2.6(b) Immune-suppressed mice
In 1914 Murphy showed that it was possible to grow and serially
passage the Ehrlich mouse sarcoma in rats pre-treated with
x-irradiation. Successful growth and transplantation of a variety of
human tumours in irradiated rodents was first reported by Toolan in
1951. Two years later she demonstrated that take rates could be
improved (90% of 101 tumours) if cortisone treatment was added and
that cortisone treatment alone could adequately immunosuppress a
mouse for xenografting.
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The development of anti-lymphocyte serum (ALS) allowed
laboratory animals to accept skin homografts (Woodruff 1963) and
heterografts from other species (Lance 1968). The major problems
associated with ALS or anti-thymocyte serum (ATS) are the production
of sufficient quantities for routine use and the standardisation of
batches. Prolonged administration of ATS may induce formation of
anti-ATS antibodies which reduce immuno-suppressive activity and lead
to immune complex formation. Tibbetts (1977) reported that mice
given ATS for longer than one month tended to become unhealthy and
tumour growth slowed after 30 days. This important point was
highlighted in a study by Mitchley (1977) who showed that hexamethyl
melamine could cure a human lung cancer xenograft grown in ATS
treated mice but did not affect the same tumour grown in
thymectomised, irradiated hosts.
Floersheim (1980) developed a short term immuno-suppressive
regime involving ALS and pre-treatment with the cytotoxic agents
procarbazine and cyclophosphamide and later compared it with other
regimes including nude mice (1982). Animals pretreated with these
agents survived longer than thymectomised or nude mice but
progressive tumour growth was not observed beyond 30 days after
implantation. Cyclosporin A was completely ineffective at producing
sufficient immunosuppression to support xenograft growth.
It seems that at present pharmacological immunosuppression would
appear to be inadequate to enable adequate tumour growth for
effective drug assessment. If immunosuppression is to be prolonged,
then these agents would have to be administered during drug testing
making the validity of such tests questionable.
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2.6(c) Immunodeficient mice
In 1961, Miller showed that the thymus played a central role in
the development of the immune response to grafted foreign tissue in
early life. He then demonstrated (1963) that the recovery of the
immune mechanism in mice following total body irradiation was thymus
dependent and if thymectomy was combined with irradiation then
animals could be rendered immunodeficient for a prolonged period.
Davies (1966) showed that irradiation doses could be increased to
normally lethal levels (850 rads) if an injection of 5 x 10^
syngeneic bone marrow cells was administered within three hours.
Castro (1972) demonstrated that an animal prepared in this way would
support the growth of a variety of human tumours.
Steel at the Institute of Cancer Research improved the
6
receptivity of the model by giving only 2 x 10 marrow cells. He
then developed an immunosuppressive regime involving neonatal
thymectomy and total body irradiation (900 rads) after a priming dose
of cytosine arabinoside (ArA-c) (Steel 1978). The rationale for
using this method was based pn the observation of Mil 1ar (1 978) that
a number of cytotoxic drugs could improve tolerance to irradiation.
Such immune deprived mice could be housed under conventional
conditions (Hay 1985) and support the growth of most human
malignancies (Steel 1983).
Although there is some evidence that the immunity of the
thymectomised/irradiated/ArA-c prepared animals may eventually
return, significant immunosuppression has been recorded up to 6
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months following irradiation (Steel 1980). This allows for
progressive growth of xenografts over a prolonged period and provides
a useful model for the testing of cytoxic agents.
2.6(d) Athymic "nude" mice
In 1966 Flanagan reported the genetic details of a hairless
mutation occurring in a closed stock of albino mice in Ruchill
Hospital, Glasgow. He called them "nude" mice (genetic symbol nu)
and confirmed that the nu gene was a single autosomal recessive. He
also noted a reduction in body growth of homozygotes and a high
mortality from hepatic necrosis. Pantelouris (1968) discovered that
the nude mouse lacked a thymus and along with heterozygotes (nu/+)
had a low leucocyte count. A preliminary report of the immunobiology
of the athymic mutant was published by Rygaard in 1969 and shortly
afterwards (1969a) he described the successful heterotransplantation
of a human colonic tumour to a nude host.
Further immunological studies (de Sousa 1969, Jordan 1977) have
demonstrated absence of lymphocytes in the thymus dependent areas of
the spleen, a normal component of B cells, small numbers of lymphoid
cells with T cell markers ( +ve cells) of uncertain functional
significance, a higher level of natural killer (NK) cells (Kiessling
1975) and an increase in macrophage activity. Other interesting
immunodeficient rodent mutants discovered since include the Lasat
mouse (Dh/nu) which is also asplenic (Lozzio 1976), the beige nude
(bg/nu) which has lower NK cells activity (Lane 1972) and the athymic
rat (rnu/rnu) (Festing 1978).
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Since 1969 all the major human cancers have been successfully
transplanted and serially grown in athymic mice in many laboratories.
Receptivity for human tumours may be further improved by
pre-treatment with ALS (Ohsugi 1980), x-irradiation (Ziegler 1982) or
cyclophosphamide (Gallie 1977).
The major disadvantages in using a nude mice colony for drug
testing lies in the cost of the animals and the fact that strict
isolation procedures and specialised husbandry techniques are
required to reduce the risk of infection and ensure a healthy colony
(Giovanella 1973). However the improved receptivity for human
tumours outweighs these problems and at present the nude mouse
remains the most widely used host for in-vivo testing of cytotoxic
agents against human tumours.
2.7 Characteristics of human tumour xenografts
2.7(a) Take rates
The vast majority of human cancers have now been grown as
xenografts using a variety of immunodeficient murine hosts.
Different centres have reported wide variations in take rates. This
may be partly explained by the use of a variety of hosts of different
receptivity, the size and form of inoculum, the technique and
location of implantation and whether primary or metastatic tumour is
used. Another major problem lies in the fact that the criteria for a
positive take varies between centres. Some workers have taken
histological evidence of 'viability' in a static nodule as proof of a
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positive take, but it is now generally accepted that the criteria for
a positive take should include progressive growth and serial
transplantabilty.
Melanoma, bronchial and colorectal carcinoms are most easily
grown with take rates of 50-80% (Steel 1983). Breast, ovarian and
testicular tumours are generally more difficult to graft. Mattern
(1985) attempted to establish 245 human bronchial tumours in nude
mice and had a positive take rate of 44%. Like Shorthouse (1980b),
he noted differences in take and growth rates with histological type,
with squamous and adenocarcinoma being most easily grown. Fogh
(1980) reported that metastases would grow more readily than primary
tumours but Mattern's data does not support this.
2.7(b) Growth Rates
Since the size of xenografts can be easily measured with
calipers, much is known about their growth rates (Steel 1977). Most
centres report tumour doubling times of between 6-20 days (Rofstad
1982, Stee 1 1983, Mattern 1985). This represents an acceleration in
growth rate after grafting since most clinical studies of tumour
growth, usually based on easily measurable metastases, show doubling
times in excess of 60 days (Steel 1983). Virtually all workers have
demonstrated an acceleration in growth rate over the first 2-3
passages in mice with stable growth rates on succeeding passages
(Houghton 1978, Steel 1983, Mat tern 1985). It is not clear whether
this is an adaptive change or a process of selection although there
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is some evidence (Houghton 1983) that it is due to a decreasing cell
loss factor rather than a change in phase duration or growth
fraction.
2.7(c) Maintenance of human characteristics
Clearly it is essential for human xenografts growing in mice to
maintain the characteristics of the original donor tumour if they are
to provide a relevant model for the study of human cancer. The
following features have been extensively studied:-
(i) Karyotyping:- The most basic requirement of human tumour
xenografts is that they maintain a human karyotype. Reeves (197S)
studied this extensively in colonic carcinoma xenografts and apart
from small changes in the distribution of chromosomes, a human
karyotype was always maintained through repeated passage. These
results have been validated by other workers in histologically
different tumours (Kopper 1975, Shorthouse 1980, Selbv 1980). It
remains important to continually check the karyotype of xenografts as
there have been reports of murine sarcomas arising at the site of
transplantation of human tumours (Houghton 1978a, Goldberg 1982,
Beattie 1982). Karyotype analysis however is time consuming and
requires considerable expertise. Some workers (Houghton 1983,
Beattie 1982) have used an electrophoretic assay which separates the
isoenzymes of lactate dehydrogenase into murine and human components
as an alternative.
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(ii) Histology:- Human tumours essentially retain the histological
and morphological characteristics of the original tumour when
transplanted into mice. Several workers have noted an increase in
differentiation of xenografts after serial passage (Sharkey 1978,
Tokita 1980), although others (Bailey 1981, Steel 1983) have reported
increased nuclear pleomorphism with a more anaplastic appearance to
many tumours. Shorthouse (1981) and Carmichael (1986) found the
pattern of production of epithelial mucins well maintained in
bronchial adenocarcinomas, a feature also noted in colonic tumours by
Houghton (1978a).
(iii) Functional activity:- Ectopic hormone production is a feature
of many human tumours and this property has been shown to persist
when these tumours are grown in mice. Havashi (1978) demonstrated
that the production of human chorionic gonadotrophin (HCG) by a human
choriocarcinoma continued when transplanted into nude mice.
S'northouse (1982) in an extensive study of human bronchial carcinoma
xenografts found evidence of secretion of HCG, calcitonin and
adrenocorticotrophic hormone (ACTH) in a significant number (13-78%).
ACTH and B melanocyte stimulating hormone (MSH) have been shown to
be produced by small cell lung cancer xenografts (Shimosato 1976).
The presence of other key biological substances such as bombesin,
neurone specific enolase and the APUD enzyme, L-dopa decarboxylase
has also been confirmed in xenografts of this cell type (Carney
1983).
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Expression of tumour related antigens such as carcino-embryonic
antigen (CEA) has been observed in colonic carcinoma xenografts
(Houghton 1978a). Raghavan (1980) studied the production of alpha
fetoprotein (AFP) by teratoma xenografts and found good positive and
negative correlations between the amounts produced in mice and in the
original patient.
2.7(d) Cachexia and metastases
It is poorly understood why human malignant tumours, which
frequently cause marked weight loss and cachexia in patients, are
unable to produce these effects when transplanted into experimental
animals, even when xenografts are allowed to grow to large sizes
(Giovanella 1974).
It is now thought that the cachexia associated with "invasive"
diseases is mediated by a multipotent protein, cachectin (tumour
necrosis factor), produced by host macrophages (Beutler 1986).
Considerable variation is observed among different species of mammals
both in the sensitivity to this protein when administered exogenously
and in the amounts of cachectin produced endogenously after challenge
with endotoxin. The production and pathophysiological effects of
this substance in immunocompromised rodents has not been studied.
Human tumour xenografts appear to lose their ability to
metastasise when transplanted to experimental animals. The reasons
for this are unclear although transplantation techniques may be
important (Fidler 1973). Many workers have noted a relationship
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between the degree of immunosuppression of the host rodent and the
occurrence of metastases (Steel 1977, Moore 1977). It is possible
that the high level of NK cell activity seen in nude mice prevents
tumour spread as metastases are much more common in beige nude mice
which have low NK cell activity (Talmadge 1980).
2.8 Drug testing using Human Tumour Xenografts
2.8(a) Methodology
It is unfortunate that as human tumour xenografts have become
increasingly popular as a screening system for anti-cancer agents, no
single effective methodology for assessing drug activity has evolved
and become universally adopted. There is little standardisation with
respect to time of initiation and scheduling of therapy, dosage
levels and assessment of response between researchers and attempts to
interrelate studies from different groups is often futile. Despite
these problems, which can only be overcome by better communications
and perhaps collaboration between groups, certain principles in the
use of xenografts for drug testing have emerged.
3
Tumour fragments (3-5mm ) or cell suspensions (approximately 5 x
£
10 cells) are inoculated subcutaneouslv in the flanks of mice. The
use of bilateral implants allows fewer animals to be used without
influencing the degree of statistical certainty (Warenius 1980). The
subcutaneous site offers the advantage that tumours may be readily
palpated and easily measured with calipers. Tumour volumes are
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calculated either by a geometrical formula or using a calibration
curve technique. It is important for tumours to be well established
at the initiation of therapy and most workers restrict drug testing
to tumours that have attained a certain volume (usually 0.3 - 1.0
3
cm ). Spontaneous regressions are rarely observed in tumours of this
size.
Groups of 6-10 tumours are then allocated to either a control
group or to treatment by one or more drugs, usually at different
dosages. The choice of drug dose is difficult and clearly critical
if the effectiveness of a series of drugs is being compared. Most
workers would agree that this problem is best approached using the
maximum tolerated dose of any drug. The rationale for this method
relates to the work of Freireich (1966) who showed a linear
relationship between the amount of cytotoxic drug that would kill 10%
of experimental mice (lethal dose 10% or LD ) and the maximum
tolerated dose in man. However it is important to remember that this
work correlated drug toxicity and not efficacy and that the
pharmacokinetics of the same drug in man and mice may be vastly
different.
After drug exposure caliper measurements are continued at
regular intervals in both treated and untreated animals. The
activity of the drug being tested can then be assessed using a number
of different methods to compare treated and control groups.
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2.8(b) Assessment of response to chemotherapy
Xenografts tend to grow as well circumscribed masses and do not
readily metastasise. The lifespan of a tumour bearing animal
therefore is not usually related to tumour burden and hence the use
of death as an experimental endpoint is not practical.
(i) Histological changes:- Several studies have attempted to
evaluate tumour response to treatment using histological criteria.
Berenbaum (1974) showed minor changes in 3 out of 44 different human
tumours treated with a variety of anti-cancer agents. Unfortunately
tumour growth following treatment was not measured. A fundamental
problem with this method of assessment was highlighted in a study of
Havashi (1978) who found necrosis, haemorrhage and degenerative
changes in both treated and control tumours.
(ii) Growth Inhibition:- This widely used method compares the
growth of treated and untreated tumours at a fixed point after drug
exposure. The inhibition of growth due to treatment is generally
expressed as a percentage of controls:
Growth Inhibition = [(1 - Treated vol/control vol) x 100]%
Since the measurement takes place at one time point, some workers
excise tumours and express inhibition using tumour weights.
A major problem when comparing results with this method lies in
deciding when the measurements should be taken. The T/C ratio
constantly changes with time until the growth rates of treated
tumours returns to that of controls. Most workers express drug
activity at 'optimal' inhibition i.e. the greatest difference between
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the two groups irrespective of time. Unfortunately if experiments
are terminated at this 'optimum' time point without regrowth of
tumours it may be impossible to distinguish between tumour shrinkage
due to drug toxicity rather than efficacy at high dosages. In
summary this method is suitable for detecting drug activity (usually
defined as growth inhibition >50%) but does not allow accurate
ranking of efficacy between active agents.
(iii) Specific Growth Delay (SGD):- This method was first described
by Kopper and Steel in 1975. The 'actual' tumour growth delay
represents the difference in time taken for a group of treated
tumours to reach a specific size (usually double the original volume)
compared with controls. If the activity of a drug is to be compared
in tumours of different growth rates then the 'specific' growth delay
can be calculated
SGD = Doubling time (treated) - Doubling time (control)
Doubling time (control)
The SGD therefore represents the number of doubling times spared by
treatment.
The fact that tumours must regrow for the SGD to be determined
overcomes the main problem of growth inhibition measurement where
acute drug toxicity may contribute to tumour shrinkage. However
there is some evidence that.the tumour cells which survive cytotoxic
treatment may regrow at a faster rate (Stephens 1977) and the SGD
cannot be measured in tumours which regress completely. Despite
this, the SGD is at present the most reliable method of assessing
drug activity in xenografts.
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(iv) Clonogenic cell survival:- Steel and colleagues have attempted
to overcome the potential influence of host rejection responses in
prolonged exposure experiments in xenografts by measuring the
clonogenic cell survival in treated tumours. Tumour bearing mice are
treated, the tumours are subsequently excised (usually after 24-48
hours), disaggregated into a single cell suspension and their ability
to form colonies in semi-solid media is evaluated. The last step can
be performed either in vitro or in diffusion chambers in vivo (Smith
1976). The main disadvantage of this method lies in the fact that
only a minority of xenografts are able to form colonies reliably.
Despite this, Steel (1983) has demonstrated a close correlation
between clonogenic cell survival and SGD,
2.9 Validity of Human Xenografts as a chemosensitivity assay
The value of therapeutic studies on human tumour xenografts
ultimately depends upon a close correlation between experimental and
clinical results. The model must either reflect the known clinical
sensitivity of the human disease or, more specifically, it should
demonstrate sensitivity similar to that of the original donor tumour.
2.9(a) Broad characteristics of xenograft responses
It is now generally accepted that chemoresponsive human tumours
give rise to xenografts which are relatively sensitive to standard
chemotherapy. This data is well summarised by Steel (1983) who
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studied both sensitive (teratoma, SCLC) and resistant tumours
(breast, non-SCLC, colon and melanoma). He showed a close
correlation between the average SGD in xenografts for drugs commonly
used in these diseases and the complete response rates reported from
large clinical studies.
(b) Direct comparison of responses with donor patients
These studies are difficult to perform because of the low
success rate in establishing xenografts and the problems of obtaining
an objectively measurable clinical response. Nowak (1978) studying
colorectal cancers and Selby (1980) using melanomas both showed that
the xenografts established from patients who subsequently showed some
clinical response were more chemosensitive when compared to other
tumours of the same histological type.
The largest study to compare directly the response to treatment
in xenografts and donor patients was performed with bronchial
carcinomas by Shorthouse (1980a, 1980b). In 16 direct comparisons (7
SCLC, 3 squamous, 5 adeno, 1 large cell) the clinical responsiveness
of 5 small cell tumours was reflected in highly responsive
xenografts. Two SCLC patients failed to respond clinically and their
xenografts were similarly resistant. All donor patients with NSCLC
failed to respond to treatment with the xenografts obtained from
their tumours also being resistant.
These encouraging results help to validate the human tumour
xenograft system as a reliable method of assessing chemotherapeutic
agents. It now seems likely that any major advance in the




INTERFERONS AND INTERFERON/DRUG COMBINATIONS AS ANTI-CANCER THERAPIES
3.1 Introduction
In 1957 Isaacs and Lindenmann discovered that living cells which
were infected with a virus produced a factor which rendered then
resistant to further infection. They showed that the immunity
conferred by the release of this factor in response to the first
"interfering" virus could also protect the cell from viruses of
different antigenic and biological type. They called this factor
Interferon (IFN). Over the next 20 years the biology and
biochemistry of IFN was steadily unravelled.
Tyrrell (1959) showed that IFN made in calf kidney cells was
inactive in chick cells and vice versa and it became clear that more
than one IFN existed. Further work has shown that a whole family of
IFNs exist depending on their cell of origin. They are complex
proteins and glycoproteins, whose production can be induced by a wide
range of stimuli and they are capable of producing profound effects
on many aspects of cellular function (Burke 1985).
Three distinct antigenic types of IFNs are recognised:
(a) Alpha interferon (IFN-a) is induced by a variety of stimuli in
many cells, the most common source being leucocytes or lymphoblastoid
cell lines.
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(b) Beta interferon (IFN-/5) is produced by fibroblasts in response
to viruses or synthetic polyribonucleotides.
(c) Gamma or 'immune' interferon (IFN->:) is an exclusive product of
T lymphocytes induced by stimulation with T cell mitogens or
antigens.
IFN-a and ft are stable in acid environments whereas treatment of
IFN-F at pH2 neutralises its activity. Only single genes have found
coding for human IFNs /3 or y . In contract up to twenty different
genes coding for IFN-a subtypes have been defined and variations in
biological activity between these subtypes have been described. IFN-a
preparations produced by genetical engineering contain products of
single IFN-a genes whereas those induced in human cells contain
multiple IFN-a gene products.
The nomenclature of IFNs (especially alpha IFN) is complex
although attempts have been made to standardise terminology (5tewart
1980, Daniels 1985). A prefix is used to designate the species of
origin (e.g. Hu for human, MU for murine), IFN is the accepted
abbreviation for interferon, followed by the designation a, /3 or)' to
indicate the antigenic type. This is then followed by a numeric or
letter designation to denote a specific subtype (e.g. IFN-a^) IFN-a
A). IFNs from particular cellular sources are similarly identified
(e.g. alpha IFN from leucocytes, IFN-a[Le], alpha IFN from
lymphoblastoid cell lines, IFN-a[Ly]). Recombinant DNA-derived IFNs
are generally preceded by the prefix 'r' (e.g. rHuIFN-a^).
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Proposals for renaming the three most commonly used subtypes of
IFN-a have recently been suggested (Daniels 1985):
(i) Interferon alpha-2a (IFN-a2a) for rIFN- ol A(Roferon-A,Roche)
(ii) Interferon alpha-2b (IFN-a2b) for rlFN-o^dntron-A, Schering)
(iii) Interferon alpha-Nl (IFN-aNl) for HuIFN-a(Ly)(Wellferon,
Burroughs-Wellcome).
Although differences exist, all classes of IFN have been shown
to possess antiviral, immunoundulatory and antiproliferative
activities. These observations led to much interest in the use of
IFN in patients with cancer. Initial studies used crude preparations
of IFN-or produced from human buffycoat leucocytes stimulated with
Sendai viruses (Strander 1973). By 1981 the molecular cloning of
human IFNs in E.coli permitted the large scale production of highly
purified single molecular species of various IFN- a s as well as IFN-/3
and y. This has allowed extensive evaluation of IFNs as anti-cancer
agents.
3.2 Interferons as anti-cancer agents
3.2(a) Rationale for use
Although originally described as anti-viral proteins it soon
became apparent that IFNs were capable of exerting profound effects
on many aspects of cellular function. They have been referred to as
"inducible inducers" (Krown 1986) since their production can be
induced by a wide variety of agents (viruses, antigens, mitogens,
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tumours etc) and their application to cells induces, in turn, the
production of a wide range of biologically active substances. The
rationale for using IFNs as anti-cancer agents is based on the
following observations:
(i) Cell division in normal and malignant cells is slowed by
exposure to IFNs (Taylor-Papadimitriou 1980, Balkwill 1977, 1978).
(ii) IFNs (especially IFN-}') can amplify effects on immune reactions
through stimulation of the different cell surface antigens involved
in cellular interactions (Basham 1983, De Haeyer-Guignard 1985).
(iii) Maturation of cytolytic macrophages is stimulated by IFNs. This
is especially true of IFN-p which is also known as macrophage
activating factor (Schultz 1978, Svedersky 1984).
(iv) IFNs enhance the activity of cytotoxic natural killer (NK)
cells (Trinchieri 1978, Perussia 1980, Strander 1986).
(v) IFNs have been shown to have important modulatory effects on
various aspects of cell differentiation in many tumour model systems
(Rossi 1985).
(vi) The amplification of certain oncogenes can be suppressed by
IFNs (Samid 1984, Jonak 1984).
(vii) The anti-viral properties of IFN may influence the growth of
virus associated neoplasia.
(viii) Various IFNs have shown activity as single agents in
laboratory models of human cancer (e.g. Bradley 1981, Borden 1982,
Strander 1977, Balkwill 1977, 1978, 1982, Aapro 1983, Heston 1984,
Hirabayashi 1985).
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3.2(b) Phase I studies
All compounds which have potential use as anti-cancer agents
must undergo extensive phase I studies before their clinical activity
can be accurately assessed. The purpose of these studies is to
define the toxicity and maximally tolerated dose (MTD) and perhaps to
give an early indication of anti-tumour efficacy.
Extensive phase I studies with both "natural" and recombinant
IFNs have now been performed in many patients (Strander 1986).
Toxicity is primarily 'flu-like e.g. fever, chills, fatigue, myalgia
and headache with some patients experiencing nausea and vomiting.
These side effects are dose-related and rapidly reversible (Spiegel
1985). Chronic studies have demonstrated that these 'constitutional'
side effects are non-cumulative and often improve with time. Early
clinical studies have often ascribed these side effects to
contaminants in impure IFN preparations. However, recent studies
using IFN preparations purified to homogeneity have shown similar
toxic effects (Tyrrel1 1985, Krown 1986).
Other side effects such as renal, hepatic, haematological and
cardiac toxicity, and CNS effects, although seen relatively
infrequently may be severe. IFN induced depression of hepatic
cytochrome P-450 activity has not been of major clinical importance
so far. The ability of this enzyme system to detoxify or activate
other drugs may prove more important as combinations of IFNs with
other agents are assessed more intensively.
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In general the MTD for alpha IFN has been highest for
recombinant DNA produced IFNs compared with HuIFN-a (Ly) or HuIFN-a
(Le). This may be related to the presence of multiple IFN subtypes
or non-IFN-proteins in the latter two preparations. Differences in
MTD have also been seen for different routes of administration (i.v.
bolus, i.v. infusion, l.M. or S.C.), for different dosing schedules
(e.g. daily -v- intermittent treatment) and when different criteria
for dose-limiting toxicity were used. In a typical phase I study
involving rHuIFN- 2b (Spiegel 1985) the MTDs were as follows: single
6 2
doses up to 200 x 10 IV/m i.v. could be given, although on a daily
6 2
dosing schedule 50 x 10 IV/m i.v. for 5 days was the MTD. For
6.2
continuous dosing, 15 x 10 IV/m s.c. 3 x/week was the MTD.
Anticancer agents in general are thought to act by direct
cytotoxicity to tumour cells and it is therefore assumed that the
largest safely tolerated dose (the MTD) will also be the dose most
likely to result in the greatest tumour cell destruction. This may
not be true for IFNs and other so called "biological response
modifiers" (BRMs) which may not exert their anti-cancer effect by a
direct action but by modifying host responses. Clearly novel
approaches are required when designing Phase I studies of IFNs and
other BRMs since the MTD in terms of subjective and/or objective side
effects may far exceed the dose required to influence a particular
cell function. Indeed certain cell functions may actually be
impaired if too low or too high a dose is administered.
Unfortunately it is unclear which, if any, of the many
measurable effector cell functions influenced by IFN treatment are
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directly related to tumour control.
To illustrate this problem many workers have assessed the effect
of prolonged IFN administration on NK cell activity in cancer
patients. No clear dose-response relationship has been demonstrated
(Krown 1986) and indeed many reports have shown decreased NK cell
cytotoxicity at higher doses (Maluish 1982, Edwards 1984). Most
studies have also demonstrated marked fluctuations in activity with
time (Golub 1982, Ernstoff 1982).
Therefore at present it is clearly impossible to define an
'optimal' dose level for IFNs from the currently reported phase I
studies. Most laboratory studies suggest that sustained exposure to
IFNs might be optimal to obtain maximum effects but until the exact
mechanisms by which IFNs exert their anti-tumour effect can be
elucidated, the scheduling of IFN therapy in patients will be based
largely on guesswork.
3.2(c) Phase II studies
Various IFN preparations have now been administered to thousands
of patients in phase II clinical studies. The activity of IFN-a in
these studies is summarised in Table 3.1. Little activity has been
seen in most adult solid tumours although it should be noted that
most of these trials have been conducted in patients with advanced
disease and may reflect inactivity against large, bulky tumours
rather than particular tumour types.
Activity has been demonstrated in a variety of haemotological
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Table 3.1: Summary of IFN-a activity in published phase II studies
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non-Hodgkin's lymphoma (Leavi11 1985) and hairy-cell leukaemia where
high response rates have been seen and IFN-Q' is now the treatment of
choice (Quesada 1984).
In some of these studies, responses occurred after 4-6 months of
treatment, so prolonged therapy may be beneficial in some cases. As
stated above, optimal dosages have yet to be determined. However in
Kaposi's sarcoma (Real 1984), renal cancer (Quesada 1983) and mycosis
fungoides (Bunn 1984) a clear relationship was established between
clinical response and IFN dose with low doses being relatively
ine f fec tive.
3.2(d) IFN and lung cancer
Clinical phase II studies of IFN in NSCLC have been negative.
The results of the five published trials are summarised in Table 3.2.
Both high and low dose regimes (all given by i.m. injection) using
various dosing schedules failed to produce significant responses.
Both natural human leucocyte and recombinant IFN-a were tested.
The reported series of IFN therapy in SCLC (summarised in Table
3.3) also shows few reports of disease response. Of the five
studies, two failed to comment on response rates, with the largest
series (Jones 1983) comprising only ten patients. High dose regimes
(up to 200 x 10^ i.u by i.v. infusion) were associated with
significant toxicity with few patients tolerating the initial
'loading' doses. A larger study is required to ascertain the true
activity of IFN in SCLC. However, the response rates reported in the
few available patients would suggest that IFN therapy is inferior to








































HuIFN-a(Le) lltilFN-u(.y) riFN-it. HuiFN-a(Le)
A'HuJFN-rt(Le) I
DosingSchedule 100-200x10i.u.,i.v.infus on dallyfor'jays 6x10i.u.,i.m.3xweek 00-100x10i.u./m'j.v.Infusion dailyfor5ays 3x10°i.u./rn2 .m,x3/weekfor1/11 OOxlui.u./m'j.v.infusion dailyfor5ays courserepeatedevery9-14days 3xl0rJi.u.,i.rn.dailyfo1/12 GxlO^i.u.,i.m x3/week'or5/12 ,o.3x10i.u.,i.m.x/week
Response Notreported None None Notreported Tbettersurvival thanuntreated 1P.R.
Reference Mattson1983 Jones1983 Jackson1983 Mattson1984 Strander (unpublished) inStrar.der 1984
Comments Untreatedpatients, severeCNStoxicity withinfusions Untreatedpatients Smallstudy (2ptshadonly1c urse) severetoxicity Allpatientshadnoi respondedtopr vi us chemotherapy Combinedwith radiotherapy
Table3.9:clinicalstud esof1FNinSCI C
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One study (Strander unpublished) combined IFN with radiation in
4 SCLC patients without much success. There have been no reports of
studies combining IFN with chemotherapy in either SCLC or NSCLC.
3.3 IFN/cytotoxic drug combinations
The complexity of the anti-tumour actions of IFNs and their
apparent failure as single agent treatment in most solid cancers has
led to interest in developing their potential as adjuvants. It now
seems likely that the most effective uses of IFN in cancer will come
in combination with other treatment modalities (Borden 1986). The
interactions between IFN and cytotoxic drugs have been assessed in
laboratory models of human cancer and reports of clinical studies of
these combinations are now appearing.
3.3(a) Pre-clinical studies
IFN/drug interactions have been extensively studied using in
vitro systems. The results of these assays are summarised in Table
3.4.
Positive or synergistic interactions between various different
IFNs and several different classes of anti-cancer agents have been
described in various tumour types using many in vitro assay systems.
The most striking synergy has been demonstrated with low doses of
IFNs (Morris 1984, Welander 1985) whi ch have little activity as a








































































Potentiation of chemotherapy by IFN using an in vivo model was
first demonstrated in 1973 by Chirigos who showed that murine IFN
could increase the cure rate of the LSTRA murine leukaemia by BCNU
from 25% to 72% despite being ineffective as a single agent. The
results of this and four other studies assessing the interactions
between murine IFN and cytotoxic agents in murine tumours are
summarised in Table 3.5. In 1984, two reports appeared of HuIFN/drug
combinations in human tumour xenografts. Heston and colleagues
treated a human renal adenocarcinoma with rHuIFN-Q'2b and
Q-difluoromethylormithine (DFMO) as single agents and in combination
in an in vitro clonogenic assay and in vivo as xenografts in nude
mice. Synergy was demonstrated in vitro using low dose IFN with
additive effects being shown in vivo. The authors commented that the
mechanism by which the drugs interacted to inhibit tumour growth was
unclear but appeared to be a direct effect on tumour proliferation,
perhaps related to modulation of polvamine metabolism.
Balkwill and Moodie at the ICRF (1984) showed that human
lymphoblastoid IFN strongly increased the activity of sub optimal
doses of cyclophosphamide and adriamycin against a human breast
cancer xenograft grown in nude mice. Further studies confirmed that
the activity of the combination of IFN and drugs was greatest when
the two agents were administered simultaneously rather than
sequentia1ly.
3.3(b) Clinical studies
The success achieved in combining IFNs and cytotoxic drugs in









BCI5U Murine leukaemia synergy
Gresser 1978 Mu CY AKR lymphoma additive
Tozawa 1982 Mu CY C1300 Neuroblastoma ? Synergy
Slater 1981 Mu Various L1210 leukaemia Synergy with
an ti-metabolites
Sunkara 1983 Mu DFMO B16 melanoma ? additive
rHuIFN-a DFMO renal carcinoma
in nude mice
additive
Balkwill 198A HuIFN-u(Lv) CY,ADR breast carcinoma
in nude mice
Synergy
Table 3.5: IFN/drug interactions using animal models
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to assess the clinical activity of such combinations. At the present
time at least 20 clinical trials of cytotoxic drug plus IFN
combinations are currently ongoing (Green 1985). Few are large
enough or have been reported in enough detail to conclusively support
or refute the concept that interferons act synergistically with any
cytotoxic agent.
Of the studies reported, only one has suggested that IFN
enhances the toxicity of anti-cancer drugs (Lonberg 1985). However,
few have reported increased activity. A major drawback to comparing
studies is the fact that many different doses and schedules of IFN
therapy are being tried varying from high dose, i.v. infusions at
weekly intervals (Welander 1985a) to low dose, s.c. injections on
alternate days (Ceto 1986).
Clearly the optimal scheduling of IFN/drug combinations in
patients cannot be rationalised until more is understood about the
exact mechanism by which IFNs may potentiate chemotherapy. Hopefully
the answers to this problem will be obtained from carefully designed
experiments using laboratory models of human cancer.
3.3(c) Possible mechanisms of IFN/drug synergy
Many of the laboratory studies of IFN/drug combinations have
proved conclusively that the increased activity seen is not due to a
simple additive effect but represents true synergy between the two
agents (Balkwill 1984, Welander 1985). Few studies have attempted to
explain the exact mechanisms involved.
Experiments using murine IFN in combination with drugs against
murine tumour models may be misleading as it is possible that some
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tumour inhibition may be due to the effects of Mu/lFN on host
tissues. Several reports have appeared in the literature showing that
MuIFN and IFN inducers can suppress hepatic cytochrome P-450
mono-oxygenase activity and thereby reduce drug metabolism (Renton
1976, Singh 1982). MuIFN has also been shown to enhance NK cell
activity in the mouse (D/jeu 1979). Both of these effects may
influence tumour growth.
Since IFNs are species specific (Tvrrel1 1959), by testing human
IFNs against human tumours in a murine host it is possible to
dissociate the direct and indirect anti-tumour actions of IFN. HuIFN
has been shown to have no effect on the hepatic drug metabolising
enzymes of the mouse (Balkwi11 1984a) or murine NK cell activity
(Balkwill 1982). Therefore the fact that HuIFN has been shown to
potentiate the effect of drugs on human xenografts in nude mice
(Balkwi11 1984, Heston 1984) would suggest that HuIFN is exerting a
direct effect on the tumour rather than the host. Also synergy has
been well demonstrated in vitro (Table 3.4) although the precise
mechanisms involved in these interactions have not been elucidated.
One study (Balkwill 1984a) has suggested that the augmentation
of drug activity by IFN may be produced by changes in tumour cell
cycle distribution. Treatment with HuIFN/CY combinations increased
the number of cells in S phase which may have accounted for the
synergy seen. These data have not yet been corroborated by others
and would not explain why synergy has been seen between IFN and drugs
whose activity is independent of cell cycle distribution (e.g. CDDP).
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Further studies to investigate how IFNs interact with cytoxic
agents are urgently required. Information gained from these
experiments may facilitate the rational use of these promising
IFN/drug combinations in patients with cancer.
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AIMS OF THE STUDY
The main aim of this study was to investigate the activity of
interferon/drug combinations in human lung cancer. The majority of
the experimental work was performed on a series of human bronchial
carcinoma xenografts established in immune deprived mice. Using this
model the effectiveness of combining recombinant human alpha-2 IFN
with a variety of cytotoxic agents was investigated in both SCLC and
NSCLC tumours. Different doses and schedules of each component were
assessed in order to determine the optimum method of administering
these IFN/drug combinations.
Similar experiments were performed in vitro by establishing
certain xenografts in continuous culture and using lung cancer cell
lines developed in other centres. Preliminary studies to elucidate
the precise mechanism by which IFNs can enhance cytoxic agents were
also performed.
The results from the laboratory experiments were used to design
a pilot study to assess the activity of human IFN and cis-platinum in
combination in a group of patients with NSCLC.
SECTION II - XENOGRAFT STUDIES
This section deals with the assessment of the effectiveness of
combining IFN with cytotoxic agents in a human tumour xenograft
system. The activity of combinations of human alpha IFN and various
drugs was compared to single agent treatment in a panel of human
bronchial carcinomas maintained in immune deprived mice. Both NSCLC
and SCLC xenografts were used for testing. Attempts were made to
define the optimum dosage schedule for combination treatment in this
model in the hope of designing an effective schedule for clinical
testing.
CHAPTER 4: Materials and methods
4.1 Source of tumours
Specimens of human bronchial carcinoma tissue were obtained from
three separate sources: (a) from surgically resected specimens from
patients undergoing thoracotomy at the City Hospital, Edinburgh (b)
from patients from the Northern General Hospital, Edinburgh
undergoing rigid bronchoscopy and biopsy for suspected tumours and
(c) from patients attending the Medical Oncology Unit at the Western
General Hospital, Edinburgh for chemotherapy who had accessible
subcutaneous metastases from small cell tumours. These lesions were
biopsied under local anaesthetic. Xenografts implanted from these
three sources were designated CX, NX and WX respectively and then
numbered consecutively.
Resected specimens were collected directly from the operating
theatre. Tumours were immediately stored on ice and then taken
without delay directly to the University Department of Pathology.
Sections of tumour tissue were taken for transplantation from
non-necrotic areas of the specimen and placed immediately into cooled
Roswell Park Memorial Institute medium (RPMI). Adjacent tissue was
fixed in formal saline prior to histological staining to confirm
malignancy.
Bronchoscopic biopsies and resected subcutaneous deposits were
obtained directly from the procedure room and divided into two parts,
one being placed in RPMI medium as above and the other being fixed
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in formal saline and sent for pathological examination. Specimens
were transported to the animal unit without delay, with the majority
of samples being implanted within four hours.
Specimens were prepared for transplantation in the animal unit
using sterile techniques under a laminar flow hood. Biopsies were
placed in cooled RPMI medium in a sterile Petri dish. All stromal and
necrotic material was removed and the remaining viable tumour tissue
was dissected using cross-scalpels into small cubes (approximately
3
5-8cm ) ready for implantation.
4.2 Preparation of immune-deprived animals
The majority of these experiments were performed using male
CBA/lac mice bred in the animal unit at the Western General Hospital.
In a few of the early studies and to maintain xenografts as stock,
some female mice were used. On the few occasions when the health of
the CBA breeding colony at the animal unit was poor, batches of newly
weaned male CBA mice were purchased from Bantin and Kingman Ltd, Hull
and used in complete experiments. The immunosuppressive regime used
in these studies is outlined in Figure 4.1 and was developed by Steel
(1978).
4.3 Anaesthesia
In the early part of the study, all surgical procedures were






Cytosine Arabinoside (200 mg/kg i.p.)
(48 hours)
Total Body x-irradiation (720-735 cGy)
(1-2 days)
Tumour Transplantation
Figure 4.1 Immunosuppresive regime for xenograft studies
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this method provided only a short period of deep anaesthesia (< 2
mins), was irritant to the animals' eyes, unpleasant for the operator
and was impractical to use without assistance.
A change was therefore made to injectable agents using a
combination of midazolam ("Hypnovel", Roche, Welwyn Garden City,
Herts) 2 mg per ml and fentanyl/fluanisone ("Hypnorm", Janssen,
Wantage, Oxon) 0.315mg per ml/lOmg per ml. A single i.p. injection
of 0.1 ml of a solution of 2 parts midazolam, 1 part hypnorm and 18
parts of water resulted in surgical anaesthesia after 5-10 minutes
lasting 10-15 minutes with full recovery in 40-60 minutes in an adult
mouse. This dose was reduced to 0.05-0.07 mis for neonatal animals
undergoing thymectomy. Excessive respiratory depression could be
reversed with naloxone (Du Pont, Stevenage, Herts) 0.lml/kg i.p.
4.4 Thymectomy
Retrosternal thymectomy was performed on newly weaned (21-28
days old) mice. Animals were anaesthetised as outlined above and
then laid in the supine position, each limb being secured by means of
a padded bulldog clip and elastic band pinned into a cork board. The
neck was extended using a paper clip and elastic band, and a cotton
wool bolster was placed between the scapulae. The skin of the neck
was cleaned with methylated spirit and a 0.5cm vertical skin incision
was made with scissors to expose the strap muscles of the neck. Both
salivary glands were displaced with forceps to expose the upper
sternum. Access to the thoracic cavity was made through a short
midline cut in the upper sternum and blunt dissection with the tips
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of the scissor to divide the origins of the strap muscles.
Both lobes of the thymus were then aspirated using suction
apparatus, the salivary glands apposed and the skin closed by means
of a surgical clip (autoclip). The whole procedure could be
performed in 2-3 minutes enabling 60-80 thymectomies to be completed
at one session. The mortality rate for the procedure in experienced
hands was approximately 5% with many deaths attributable to the
anaesthetic.
4.5 Irradiation
3-4 weeks after thymectomy the mice were given a single i.p.
injection of cytosine arabinoside (Upjohn, Crawley, W. Sussex) to
protect the gastro-intestinal tract and bone marrow from the lethal
effects of irradiation (Millar 1978). Two days later, they were
irradiated using 250 kVp x-rays with Thoraeus Ii filtration. During
irradiation the mice were placed in a 15cm diameter, 2.5cm high
perspex jig. Ten mice could be accommodated at any one time and they
were free to move about the jig during the period of irradiation.
The jig was positioned in the centre of a 20x20 cm irradiation field
at a focus-jig distance of 62cm. The mean radiation dose rate was
37cGy/min + 2%.
In order to eliminate variations in dose due to varying dose
rate, synchronous dosimetry was performed during all animal
irradiation. A previous study reported by Hay (1985) using this
equipment showed that the mean dose in the jig was 94.5% of that
measured by the ionisation chamber (95% confidence limits + 0.98%).
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The dosimeter was calibrated for room temperature and atmospheric
pressure for each run and ensured accurate x-ray dosing.
Previous studies using irradiated mice as hosts for human
tumours (Davies 1969, Steel 1978, Kovnat 1982) have given doses of
850-1000 cGy using either ^Co or ^~^Cs sources. The Relative
Biological Effectiveness (RBE) value of ^Co }'-rays when compared to
250kVp x-rays for the whole body irradiation of mice is 0.8 (Green
1962). Therefore the dose of x-rays used in these studies
(720-735cGy) was comparable with these earlier reports. Hay (1985)
showed that the optimum x-ray dose with this system to ensure high
tumour take rates and acceptable survival was 735cGy.
Following irradiation, animals were commenced on antibiotic
therapy with oxytetracyc1ine (Terramycin, Pfizer Ltd, Sandwich, Kent)
lOOmg and neomycin (Neobiotic, Upjohn, Crawley, W Sussex) lOOmg added
to each litre of drinking water for 14 days to prevent septicaemia
from commensal gut flora. During this time animals were fed standard
diet softened by soaking in acidified water to aid nutrition.
4.6 Tumour implantation
Tumour fragments were implanted the day following irradiation.
When this procedure is delayed until 7-14 days it is associated with
an increased mortality (Carmichael 1986). Animals were anaesthetised
and secured on their ventral surface. The skin was cleaned with
methylated spirit and a 1cm transverse incision made with scissors in
the mid-dorsal region. Subcutaneous tracks were fashioned with blunt
forceps along the lateral aspects of both flanks. Tumour fragments
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(approximately 8mm ) were implanted subcutaneously near the axillae.
The skin was closed with a surgical clip (autoclip) and the mouse
identified using numbered ear tags (Hauptner).
4.7 Animal husbandry
After thymectomy mice were kept in a separate room reserved for
immune suppressed animals. The room temperature was controlled by-
thermostat with 12 hours of light each day. Air was filtered when
drawn into the building but specific pathogen free conditions were
not required. Staff entering the room were kept to a minimum and
wore gowns and overshoes.
The mice received a standard laboratory diet (CRM expanded,
Labsure, Poole, Dorset), their drinking water being acidified to
reduce the risk of pseudomonas infection. Standard animal boxes and
bedding were used, both of which were autoclaved before use.
4.8 Tumour Passage
3
When tumour xenografts attained a volume of 0.5-1 cm they were
considered suitable for transplantation to a subsequent generation.
The host animals were sacrificed by cervical dislocation and the
tumours removed aseptically. All necrotic tissue was removed and
3
small fragments (approximately 6-8mm ) were produced using
cross-scalpels. These fragments were kept in a petri dish of RPMI
medium prior to subsequent implantation into freshly prepared
animals. All procedures were carried out in a laminar flow hood.
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At each passage, sections of tumour were taken for histological
analysis and karyotyping was performed at regular intervals.
4.9 Storage of tumours
Wherever possible, tumour samples from the original specimen and
early passages were stored in liquid nitrogen. Tumour tissue was
dissected as previously described into small cubes. Ten cubes were
placed into a plastic freezing vial containing 1ml of 10% dimethyl
sulphoxide in foetal calf serum. The vials were placed in a -40°c
freezer overnight prior to transfer into liquid nitrogen.
When specimens were required for implantation they were removed
from the liquid nitrogen and rapidly thawed. The tumour fragments
were aspirated with a pastette and washed repeatedly in RPMI medium
at room temperature. Implantation was then carried out with minimal
delay.
4.10 ,Hi stopathology
Sections of original tumour tissue and specimens from xenografts
at each passage were assessed using standard histological techniques.
Samples were fixed in formal saline, embedded in paraffin wax and
sectioned at 4.4um. Sections were placed on microscopic slides, the
paraffin removed by treatment with xylene which was further removed
with ethanol. All specimens were stained with Ham's haematoxylin and
Putt's eosin in the standard manner. Adenocarcinoma xenografts were
stained with periodic-acid schiff (PAS) to assess mucin production.
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This technical work was performed by the department of Pathology,
Western General Hospital.
All slides were examined by Dr M Mclntyre, Consultant
Pathologist, Western General Hospital who made a histological
diagnosis on the original tumour specimens and compared sections
taken at subsequent passage for changes in the level of
differentiation, amount of inflammatory infiltrate, mucin production
and the presence of stromal tissue.
A. 11 Chromosome analysis
The maintenance of a human karyotype by xenografts was checked
by making chromosome preparations using the direct method described
by Simoni (1983). Xenografts were removed using sterile techniques
and placed in RPM1 medium containing 5% foetal calf serum and
glutamine. Non viable tumour tissue was removed by dissection and
the remaining tumour was transferred to a fresh petri dish. The
specimen was then chopped finely using dissecting scissors and
scalpels until fragments of explant size were left. These pieces
were then incubated in Colcemid (Gibco) at a final concentration of
O.OAmg/ml in lOmls RPMI for 2 hours at 37°C. After centrifuging at
1700 rpm for 5 mins the medium was removed and replaced with lOmls 1%
sodium citrate. After incubating at 37°C for 20 minutes the
hypotonic solution was removed and lOmls of 3:1 methanol:acetic acid
o
fixative was added. The preparation was left overnight in a -20 C
freezer. The following day the fixative was removed by
centrifrugation and replaced with 2-3mls of fresh 3:1 fixative. The
xenograft pieces
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were then removed and placed on a warm (40°C) clean slide. The
fixative was then blotted dry with filter paper. A few drops of 60%
acetic acid were added to the xenograft material and left for one
minute. The xenograft pieces were then pulled slowly up and down the
slide with the bent tip of a pasteur pipette until the acid had
evaporated. Slides were then checked for mitoses and the best
preparations were stained in 5% Giesma in Gurrs Buffer (pH 6.8) for
10 minutes. Human morphology of the chromosomes was then confirmed
by direct microscopy.
4.12 Tumour measurement
Following tumour implantation, the animals were left undisturbed
until a lump could be easily palpated or was clearly visible in the
flank. The hair was then shaved over the xenografts and measurements
made using calipers. Tumour volume was estimated assuming an
ellipsoid shape. Any xenografts of awkward shape were not used in
drug testing experiments. The longest and shortest perpendicular
diameters were measured three times and the mean taken as the final
measurement. Tumour volume was calculated using the equation:
, 2
volume = 7i x D x d
6
(D = longest diameter, d = shortest diameter)
The accuracy of these measurements was assessed by correlating the
estimated volume using calipers with the weight of the excised
tumour. This was performed for a range of tumour sizes and different
histological types.
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In general, tumours were measured three times per week and the
time taken for the tumours to double from a specific starting volume
3
(usually between 0.25 and 0.75cm ) was estimated to determine the
growth rate. The take rate for each tumour type was defined as the
proportion of implants that progressively grew to a palpable size and
was usually expressed as a percentage.
4.13 Assessment of chemotherapeutic agents
The majority of the work of this study involved assessing the
activity of cytotoxic drugs administered as a single agent and in
combination with IFN in the human lung tumour xenograft model.
For these experiments a group of animals of the same sex
underwent thymectomy as one batch, the number of animals chosen
depending on the take rate of the tumour being used. These animals
were then irradiated at one session and tumour fragments were
implanted the following day. When sufficient tumours had attained a
3
volume of 0.25 - 0.75cm they were divided into groups stratifies for
tumour size. Attempts were made to keep the number of tumours ir.
each group at a reaonable level (8-10), groups with fewer than 6
tumours were considered unsuitable for drug testing.
In a hypothetical experiment where three treatment regimes were
assessed in a tumour with a take rate of 70% (e.g. NX002), 50 animals
would undergo thymectomy. Two would die post operatively, leaving 48
to undergo irradiation and transplantation with bilateral implants.
A further 5 may be lost through irradiation toxicity and intercurrent
infection, leaving 43 animals. With a take rate of 70%, this
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represents 60 tumours. Of these, 15 would show insufficient growth
and 5 would be of unsuitable shape, leaving 40 measureable tumours of
useable size. These would be divided for assessment into four groups
of ten tumours, a control group and three treatment groups, the
allocation of groups to a specific treatment being randomised.
Chemotherapy was then administered often based on the maximum
tolerated dose on a milligram per kilogram basis. All cytotoxic
agents were dissolved in water for injection or normal saline and
injected intraperitoneally except for the nitrosurea TCNU which was
dissolved in polvetheylene glycol (PEG 400) and given orally by a
gavage needle. All agents were prepared in a final concentration to
allow their administration in a volume of 0.1ml per 10 grams body
weight. Control animals were given injections of saline in an
identical schedule to treated animals.
Caliper measurements were then continued three times weekly
until the end point of the experiment which was usually when all
tumours had doubled in volume or completely regressed. Wherever
possible, the activity of one agent or combination of agents was
expressed in terms of the specific growth delay (SGD). This figure
was derived from the median doubling times (TD) of treated and
control groups using the equation:
SGD = TD (treated) - TD (control)
TD (control)
The SGD represents the number of doubling times prolonged by
treatment and allows comparison between tumours of different growth
rates. A hypothetical experiment illustrating the use of SGD in
shown in Fig 4.2.
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Expression of drug activity in terms of SGD allowed for
comparison between tumours of differing growth rates but did not
allow statistical comparisons between different agents and
combinations of agents. Comparison of doubling times for groups of
tumours receiving different treatments was difficult since the data
was not normally distributed and non parametric tests were required.
Also such tests could not include data from tumours which regressed
completely or remained static in size.
Expert statistical advice was obtained and it was decided to
compare the efficacy of treatments by calculating the slope of the
growth curve for each tumour from the knowledge of its doubling time
(or halving time in regressing tumours). This slope (D) was
calculated as:
D = log size
e
TD (days)
(size = 2 for doubling tumours, 1 for static and 0.5 for regressing
tumours). For example;for a tumour doubling in 7 days:




A regressing tumour which halved in size in 25 days:
D = logg 0.5 = -0.03
25
Static tumours would obviously have a slope of zero.
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The mean slope for each treatment group was then calculated and
differences between groups were assessed by analysis of variance.
Interactions between IFN and drugs with combination treatment was
assessed by 2-way analysis of variance using a factorial design.
This allowed the nature of any interaction (additive, synergistic or
antagonistic) to be determined.
4. 15 Drug dosage and Toxicity
In most reported studies of drug testing using xenografts,
agents are administered once at the maximum tolerated dose (MTD).
This allows ranking of drugs based on their anti-tumour activity. To
find the MTD of a drug, a full dose response experiment should be
conducted and the dose of drug causing death in 10% of animals over a
30 day period (the L^q) calculated. For most drugs, the MTD is
considered to be aDproximately 80-90% of the Lfjg'
In the studies of IFN/drug combinations reported here, an
attempt was made to give the xenograft a chronic exposure to the
cytotoxic agents and IFN and therefore many of the schedules
described involve lower doses than the MTD given repeatedly e.g. 20%
of MTD x 5 at weekly intervals or 50% of MTD x 2 at 10 day intervals.
In some cases (e.g. NX004), full dose/resnonse experiments were
performed to ascertain the MTD for certain agents. Other workers
(Stee 1 1983, Carmichael 1986) have published estimates of MTDs for
drugs in thymectomised, irradiated, tumour bearing mice and these
reports were used to plan the schedules of the other experiments.
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4.16 Interferon
The interferon used in this study was the human recombinant
alpha 2 subtype (rHuIFN-^2b). It was kindly supplied by the Schering
Corporation, Bloomfield, New Jersey. It has a specific activity of
g
1.7 x 10 u/mg of protein. The purity of the product has been
established by reversed phase HPLC to be greater than 98% pure
(Nagabhushan 1985). Large scale production of this IFN has used the
KMAC-43 strain of E.coli, the alpha-2 IFN gene being obtained from a
cDNA clone, Hif-SN206 (Streuli 1980).
Freeze-dried IFN was thawed and dissolved in water for
injection. It was administered daily in all schedules, injected
subcutaneously diluted appropriately in a volume of 0.1ml, at a site




This short section deals with the preliminary experiments
pertaining to the establishment, characterisation and maintenance of
the panel of human lung cancer xenografts used in drug testing.
5.1 Establishment of xenografts
A panel of eight bronchial carcinoma xenografts have been
established in immunodeficient CBA mice using the techniques outlined
in chapter 4 (Plate 5.1). Much of this work was performed by Dr J
Carmichael and has been reported in detail in his MD thesis (1986).
The characteristics of these xenografts are summarised in Table
5.1. All the common histological types of lung cancer are
represented with CX143 being of the rarer mixed adenocarcinoma and
squamous type. The majority of tumours were grown from specimens
resected at thoracotomy with two lines being established from
endobronchial biopsies. The two small cell xenografts (NX004 and
WX322) were grown from subcutaneous tumour deposits removed under
local anaesthesia.
The take rate of specimens transferred from patient to mouse
(passage 0) was approximately 20%. Once established as a xenograft,
take rates varied with histological type and tended to increase with
the number of times the tumour had been passaged (Table 5.1)
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Growth rates, measured as the time taken for the tumours to
double in volume after reaching a measurable size, were prolonged in
early passages with some doubling times as long as 4-6 weeks. With
serial passage these times shortened to 8-18 days and after the 4th
or 5th passage remained fairly constant. Drug testing was not
performed at these early passages.
5.2 Histological monitoring
Histological examination of the tumours was performed prior to
the initial implantation and at each subsequent passage. This work
was kindly performed by Dr M A Mclntyre, Consultant Pathologist,
Western General Hospital. In general, little change was seen in the
histological apearance of the xenografts compared to the original
donor tumour despite serial passage over many months (Plates 5.2 and
5.3). No significant changes were seen in the level of
differentiation of the xenografts although some tumours-tended to
become slightly more differentiated with repeated passage. Mucin
production in the adenocarcinoma (CX117) remained constant with time.
The mixed adeno-squamous tumour (CX143) showed prominence of the
squamous element after 24 months in mice, with only scant evidence of
mucin producing elements after this time.
5.3 Karyotyping
Chromosome analysis was performed on all xenografts after the
Plate 5.2: Xenograft NX002, moderately differentiated squamous
carcinoma, original donor specimen (subcutaneous deposit), April
1985 (H and E, x 200)
Plate 5.3: Xenograft NX002, 6th passage, June 1986, showing little
change from original specimen shown in Plate 5.2 (H and E, x 200)
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5th passage to ensure that a human karyotype was maintained. This
work was kindly done by Ms Sandra Lawrie. Repeat analysis using the
G-ll technique was performed on all tumours in January 1987 with no
evidence of murine chromosomes being evident (Plate 5.4).
5.4 Animal health
The thymectomised, irradiated CBA mice used to bear xenografts
were kept in a standard room in the animal unit without elaborate
precautions to avoid pathogens. Antibiotics (terramycin and
neomycin) were added to the drinking water for 14 days after
irradiation in an attempt to reduce the incidence of septicaemia from
commensal gut flora.
Despite this, a small number of mice (approximately 5%) would
develop a wasting syndrome which in thyraectomised mice is thought to
be due to chronic infection with mouse hepatitis virus (MHV-1)
(Sparrow 1980). Occasionally a more virulent infection would occur
and large numbers of mice (up to 50% in any batch) were lost. These
episodes were usually self-limiting and drug testing was not
attempted with these mice.
In the summmer of 1986, a more serious infection occurred with
whole batches of mice being lost. Affected animals had rapid
breathing, wasting and occasionally paralysis of hind legs. These
features were noted about 3-4 weeks after tumour transplantation.
The infection did not appear to spread from cage to cage but became
"endemic" in batches of mice which were thymectomised at the same
t ime.
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Plate 5.4: Chromosome preparation from xenograft NX004
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Histology of the lungs from infected animals showed necrosis of
bronchial epithelium and alveolar hyperplasia with haemorrhage and
inflammatory infiltrate within the alveolar spaces. The slides were
reviewed by Dr Philip Carthew of the MRC Experimental Embryology and
Teratology Unit, Carshalton, Surrey and Andor Sebesteny, Veterinary
Surgeon, ICRF Animal Unit, Clare Hall, South Mimms, Herts who both
felt the likeliest cause of the changes was acute Sendai virus
infection. However, raised titres of antibodies against Sendai virus
were not detected in serum taken from affected animals.
It was noted that infection only occurred in batches of mice,
was unusual in non-tumour bearing animals and very common in certain
xenograft lines (NX004 and NX002). Dr Carthew speculated that the
virus may have been spread by transplantation of the tumours since
Sendai virus will grow in cells of many different species including
man. An attempt was therefore made to assess the ability of the
xenografts to transmit infection.
A large tumour (NX004) was excised from an affected animal and
placed immediately into liquid nitrogen. The xenograft was sent
frozen directly to Dr Carthew and Dr Auriol Hill at the MRC unit in
Carshalton with specimens of the liver and lungs of the donor animal
transported in formal saline. On arrival the tumour was frozen and
thawed three times and then administered to 10 MF1 and 6 nu/nu mice
by the intranasal and intraperitoneal route. After four weeks the
mice all remained healthy. Serum from the MF1 mice showed no
antibodies against mouse Hepatitis virus, Pneumonia virus of mice,
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Sendai virus or reovirus III. No mycoplasma were isolated from any
of the mice. Histological examination of the salivary glands, lungs,
liver, spleen and gut showed no abnormalities, with no evidence of
any virally transmitted disease. Histology of the donor animals'
lungs showed the classical changes of acute viral infection described
above. The liver was normal. Therefore it seemed clear that the
infection was not being spread via the tumours.
Dr Hill felt that it was possible that the mice were infected
with a human pathogen such as para-myxovirus or reovirus and held
reservations about the accuracy of serological testing of serum from
immunosuppressed animals. After 6-8 months the infection became less
virulent and drug testing was restarted.
5.5 Accuracy of caliper measurements
The volume of tumour xenografts was calculated from two
perpendicular diameters assuming an ellipsoid shape. To verify the
accuracy of this technique, twenty xenografts of varying size and
histological type were selected and their volume estimated with
caliper measurement. The tumours were then excised and weighed. A
good correlation between estimated volume and actual weight was
obtained for all histological types (Figure 5.1), even for tumours
considered too small or too large for drug testing.
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Figure 5.1: Correlation between estimated tumour volume by caliper




Activity of IFN/drug combinations in NSCLC xenografts
6.1 Introduction
This section describes experiments performed to assess the
anti-tumour activity of human alpha IFN and various cytotoxic drugs
administered both as single agents and in combination in two human
NSCLC xenografts.
Preliminary studies using these tumours (Carmichael 1986) had
shown promising interactions between CDDP and human lymphoblastoid
IFN, particularly in the adenocarcinoma, CX117. The dose of IFN used
(2 x 10 units/mouse/day for 35 days) produced a significant
cytotoxic effect when administered as a single agent. This dose of
6 2
IFN is equivalent to approximately 20 x 10 units/m daily in humans
using the calculations of Freireich (1966) and would be unlikely to
be tolerated by patients. The experiments reported here were
designed to mirror more closely the clinical situation. A
recombinant IFN preparation (rHu IFN-c*2b) was used as we had clinical
experience of its action and planned to use it in further clinical
studies. This IFN contains only the <*-2 subtype of IFN-n unlike
human lymphoblastoid IFN which contains several IFN-® subtypes. Mice
were treated with lower doses of IFN (2 x 10 units/day), the
equivalent of which would probably be well tolerated by patients.
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Since other studies investigating the interaction between IFN
and drugs using xenografts (Balkwi11 1984, Heston 1984) had shown
evidence of synergy when chronic exposure to combinations was used,
an attempt was made to administer the two agents repeatedly over a
prolonged period rather than a single, maximally tolerated exposure.
IFN was given subcutaneously on a daily basis while various cytotoxic
agents were injected i.p. at 20% of their MTD x 5 at weekly intervals
or at 50% of their MTD x 2 at a 10 day interval. Further studies
investigating the optimum dosage schedules of IFN and drugs are
outlined in Chapter 8.
The two NSCLC xenografts used in these studies were: (i) NX002,
a moderately differentiated squamous carcinoma and (ii) CX117, a
poorly differentiated adenocarcinoma. Drug testing was not performed
before the 5th passage and the majority of experiments were performed
between the 7th and 20th passages. Only tumours produced from one
passage were included in any one assessment of an agent or
combination and this passage number (e.g. NX004/12) is detailed for
each experiment.
As detailed in Chapter 4, the activity of IFN/drug combinations
was assessed by randomly allocating groups of 6-10 tumours to
treatment with either the drug or IFN as a single agent, IFN/drug in
combination, or to a control group. Tumours were measured three
times weekly and an estimation of the tumour doubling time (TD) for
each tumour was made. The median TD for each group was then
calculated and the activity of any treatment expressed where possible
in terms of the SGD compared to controls. Statistical comparisons
were performed as outlined in Chapter 4. Complete regression or
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stasis in growth of any xenograft or significant toxicity was noted.
In the initial experiments (6.2-6.7) the activity of IFN-^2b in
combination with three commonly used drugs (CDDP, ifosfamide and
cyclophosphamide) was studied in both NX002 and CX117. In the
subsequent experiments (6.8-6.12) other cytotoxic agents were
assessed with IFN-°^2b in NX002 only.
6.2 CDDP and IFN in NX002/10
CDDP was administered i.p. in a dosage of 1.4 mg/kg (20% of MTD)
on days 0, 7, 14, 21 and 28. IFN was injected s.c. in a dose of 2 x
4
10 units/mouse/day for 35 days. The effect of this treatment on the
growth of the xenografts is shown in Figure 6.1. The median TD for
control tumours was 9 days. IFN at this dosage had no effect as a
single agent (median TD = 10 days; SGD = 0.11). Treatment with CDDP
alone caused a significant increase in TD compared to controls
(median TD = 17 days; SGD = 0.88). The addition of IFN to CDDP
increased the potency further (median TD = 27 days; SGD = 2.0).
Three tumours (1 CDDP alone, 2 CDDP and IFN) regressed completely in
this experiment. No significant toxicity from any treatment was noted
and there were no treatment deaths. The interactin between CDDP and
IFN was additive (F = 0.224, p = 0.639)
6.3 CDDP and IFN in CX117/10
CDDP and IFN were administered as single agents and in
combination using the same dosage schedule used in 6.2. Control
tumours had a median TD of 12 days. IFN alone had no effect
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Fig 6.1: Inhibitory effect of CDDP/IFN combination on the growth
of NX002/10 (growth expressed as the mean % of the original volume)
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(median TD = 11 days). CDDP alone caused a small increase in the
median TD to 14 days (SGD = 0.16). The combination of IFN and CDDP
gave a significant prolongation of the mean TD (median TD = 18.5
days; SGD = 0.54). This interaction was synergistic (F = 5.732,
p = 0.025)
6.4 IFOS and IFN in NX002/11
IFOS was given in a dosage of 60mg/kg (20% MTD) i.p. at weekly
intervals x 5 in an identical schedule to CDDP. IFN (2 x 10^ units)
was given daily s.c. for 35 days. The inhibitory effect of this
treatment on the growth of NX002/11 is shown in Figure 6.2. Control
tumours doubled in a median of 9 days. IFN had no effect as a single
agent (median TD = 10 days; SGD = 0.11). IFOS had little activity
alone (median TD = 11.5 days; SGD = 0.27) but when IFN was added an
increased effect was seen (median TD = 15 days; SGD = 0.66). However
this interaction was not significantly synergistic (F = 3.665,
p = 0.06).
6.5 IFOS and IFN in CX117/10
IFOS and IFN were administered in an identical schedule to that
used in 6.4. Median TD for the control group was 12 days. IFN as a
single agent had no effect (median TD = 11 days). IFOS alone had
similar activity as CDDP alone in this xenograft (median TD = 14
days; SGD = 0.16). The addition of IFN to IFOS improved its potency
-104-
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gure 6.2: Inhibitory effect of IFN and IFOS on the growth
of NX002/11. Results are recorded until the time of
tumour doubling
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(median TD = 16 days; SGD = 0.33) in an additive manner (F = 0.934, p
= 0.34). One tumour in the IFOS alone group regressed completely.
Overall NX002 appeared to be a more chemosensitive xenograft
line than CX117. The median TDs and SGDs for CDDP and IFOS alone and
with IFN in NX002 and CX117 are shown as histograms in Figures 6.3
and 6.4.
6.6 Cyclophosphamide (CY) and IFN in NX002/15
CY was assessed in a similar manner to CDDP and IFOS above. It
was injected in a dose of 40mg/kg i.p. at weekly intervals x 5. IFN
was given as above (2 x 10^ u/mouse/day). The effect of CY with and
without IFN is shown in Figure 6.5. Control tumours had a median TD
of 7 days. IFN had no effect as a single agent (median TD = 7 days).
Treatment with CY alone was relatively ineffective (median TD = 8
days; SGD = 0.14) but was enhanced when IFN was added (median TD = 12
days; SGD = 0.71). This was an additive interaction (F = 0.648, p =
0.42). One tumour in this CY/IFN group regressed completely.
6.7 Cyclophosphamide and IFN in CX117/13
CY and IFN treatment was scheduled as in 6.6. The effect of the
two treatments given singly and in combination is shown in Figure
6.6. Control tumours had a median TD of 11 days. Tumours treated
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Figure 6.3: Effect of IFN, CDDP and IFOS alone and in combination
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Fig 6.4: Effect of IFN, CDDP and IFOS alone and in combination
on the SGD of the two NSCLC xenografts NX002 and CX117
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Fig 6.5: Effect of cyclophosphamide and IFN on NX002/15
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Fig 6.6: Effect of cyclophosphamide and IFN in CX117/13
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CY alone had little activity (median TD = 12 days; SGD = 0.09). CY
combined with IFN was more effective (median TD = 17 days; SGD =
0.54). However this interaction did not reach significance for
synergy (F = 3.0, p = 0.097).
6,8 Platinum analogues and IFN in NX002/18
After demonstrating that IFN- 2b may enhance the activity of
CDDP in NSCLC xenografts (sections 6.2 and 6.3) further studies were
designed to ascertain whether a similar effect could be demonstrated
using synthetic analogues of CDDP. Two compounds were tested: (i)
CBDCA (carboplatin, JM8) and (ii) JM40 (melonato platinum). Both
were given using a chronic dosing schedule with and without IFN in
the squamous carcinoma xenograft NX002.
6.8 (a) CBDCA and IFN in NX002/18
CBDCA was administered at a dose of 15 mg/kg i.p. x 5 at weekly
4
intervals. IFN was given in the usual schedule (2 x 10 u/mouse/day
for 35 days). The effect of single agent and combination therapy in
the growth of the xenograft is shown in Figure 6.7. The median
doubling time for the control group was 8 days. IFN alone had no
effect on tumour growth (median TD = 7 days). CBDA as a single agent
had a profound effect. Of the seven tumours tested, three doubled in
size (13, 18 and 23 days), two regressed completely and two (double
tumours on one mouse) died after the first week of the experiment.


































































Enhanced activity was seen with the CBDCA/lFN combination group. Of
the seven tumours tested no tumour doubled in size, two remained
static at <50% of their original volume and five regressed
completely. The interaction between IFN and CBDCA however was
additive (F = 3.448, p = 0.07).
6.8 (b) JM40 and IFN in NX002/18
JM40 was given i.p. at 8mg/kg using an identical schedule to
CBDCA. IFN was also administered as above. The effect of single
agents and the combination of JM40 and IFN on tumour growth is shown
in Figure 6.8. The control group was the same as used in 6.8(a) and
doubled in 8 days. IFN alone had no effect (median TD = 7 days).
JM40 alone also appeared to have no activity (median TD = 8 days).
The JM40/IFN combination group had a median TD of 11 days (SGD =
0.37) with one tumour in the group remaining static. This
interaction appeared additive (F = 1.65, p = 0.21).
The efficacy of the JM40/IFN combination treatment became more
apparent after the first 10 days of the study (Figure 6.8). The
calculation of the SGD from the first doubling time of the tumours
would therefore tend to underestimate the activity of the combination
group in a chronic experiment. If the time taken for the tumours to
reach three times their starting volume (trebling time or Tt) is
used, then possibly a more accurate estimate of the activity is
perhaps made. Median Tt for the controls was 15 days, for IFN alone
was 13 days and for JM40 alone was 18 days (SGD = 0.2) while only one















original volume (in 23 days). The interaction between IFN and JM40
at this stage was strongly synergistic (F = 10.532, p = 0.003)
6.9 Adriamycin (ADR) and IFN in NX002/20
ADR was administered at a dose of 6mg/kg (50% of MTD) i.p. on
4
days 0 and 10. IFN was given s.c. at 2 x 10 u/mouse daily for 20
days. Control tumours doubled in 10 days. The group treated with
IFN alone had a median TD of 11 days (SGD = 0.1). ADR as a single
agent had no effect on the tumour (median TD = 9 days). ADR in
combination with IFN caused a small increase in median TD to 13 days
(SGD = 0.3). Additivity was therefore seen (F = 0.31, p = 0.57).
6.10 Vindesine (VND) and IFN in NX002/21
VND was given in a similar schedule to ADR in 6.9 i.e. 50% of
A
MTD (lmg/kg) i.p. on days 0 and 10. IFN was given s.c. 2 x 10
units/mouse daily for 20 days. The median TD for controls and IFN
treated tumours was 11 days. VND as a single agent had no
significant activity (median TD = 10 days). VND and IFN in
combination caused an increase in median to 17 days (SGD = 0.55).
Statistical analysis suggested additivity had occurred between VND
and IFN (F = 0.74, p = 0.39).
6.11 Etoposide and IFN in NX002/21
This experiment was performed on the same batch of tumours as
used in 6.10. Etoposide was given as 50% of the MTD (15mg/kg) i.p.
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oa days 0 and 10. The control group and IFN treated tumours both had
a median TD of 11 days. The group of tumours treated with etoposide
as a single agent had a median TD of 6 days and those treated with
the combination of etoposide and IFN doubled in 9 days showing no
activity for either treatment and no positive interaction occurred
(F = 0.33, p = 0.57).
6.12 TCNU and IFN in NX002/20
In 1986 an opportunity arose to test a new nitrosourea in the
xenograft system. TCNU is a unique water soluble
dimethylamino-sulphony1 nitrosourea based on the endogenous
aminoethane sulphonic acid, taurine. It has shown activity against
experimental rodent tumours and the parent drug can be detected in
the plasma in man up to 8 hours after a single oral dose.
TCNU was dissolved in polyethylene glycol and administered by
oral gavage at 10 mg/kg (50% of MTD) on days 0 and 10. IFN was given
daily in the usual dose for 20 days. Control tumours had a median TD
of 10 days. IFN treated tumours doubled in 11 days (SGD = 0.1).
Treatment with TCNU alone caused a significant delay in growth
(median TD = 25, SGD = 1.5) with two of the ten tumours in the group
remaining static. Only four tumours doubled in the TCNU/IFN
combination group (8, 15, 20 and 22 days), four remained static and
two animals died. Significant toxicity indicated by weight loss and
diarrhoea was seen in both groups receiving TCNU but was not
apparently worsened by the addition of IFN. This interaction was
additive in nature (F = 0.025, p = 0.87).
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6.13 Discussion
In all the experiments described above, the activity of small
doses of cytotoxic drugs against the two NSCLC xenografts was
enhanced by the addition of low doses of human alpha IFN. IFN alone
at this dose had no significant effect on the tumours. The results
are summarised in Table 6.1 with activity of each agent being
expressed in terms of the SGD with and without IFN.
Unfortunately in some of the exoeriments measurement of the SGD
gave a poor indication of the activity of a treatment regime. CBDCA
was clearly an active agent in NX002 but measurement of the SGD was
impossible, as fewer than 50% of the tumours doubled in size and
therefore a median TD could not be calculated. The activity of the
JM40/IFN combination was perhaps also underestimated by calculating
the SGD from the first doubling of the tumour from the onset of
treatment. Figure 6.8 illustrates that the effect of treatment with
the combination compared to the other groups only became apparent
afer the first 2 or 3 JM40 treatments (approximately 10 - 14 days)
and the activity of the combination was therefore underestimated by
measuring the first doubling time. It is perhaps unfortunate that in
this model survival is not influenced by tumour growth and cannot
therefore be used as an end point.
Although it has been demonstrated that the combination of IFN
and chemotherapy would seem to be more effective than would be
expected from the potency of each as a single agent, not all
interactions proved to be statistically synergistic. However,
























































* Insufficient tumours doubled to calculate SGD (see text)
Table 6.1 Activity of various drugs in NSCLC xenografts expressed as
SGD with and without IFN (SGD for- IFN alone = 0.1). The values in
the far right column denote the p value for the "significance of
interaction" between the drug and IFN in combination (p<0.05
suggesting a positive effect). All experiments were performed once
although IFN and CDDP in NX002 was repeated in Chapters 8 and 9.
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fell just short of statistical significance. Perhaps repeat
experiments with larger groups of tumours would be more helpful in
defining the precise nature of any interaction between IFN and drugs.
The clinical studies of treatment with IFN discussed in Chapter
3 have not defined a dose-response effect and the optimal schedule of
administration remains to be determined. In some tumours the
duration of therapy seems to be at least as important as the dose
administered. It was for these reasons that these combination
experiments were designed to explore the use of IFN and cytotoxic
drugs scheduled repeatedly over a period of weeks, rather than a
single maximally tolerated exposure. IFN was administered daily and
the cytotoxic agents given as 20% or 50% of the MTD in divided doses.
Studies to define the optimum dose schedule for these IFN/drug
combinations are described in Chapter 8.
The majority of cytotoxic drugs used in these experiments were
alkylating agents although some enhanced activity was seen with
adriamycin and vindesine. Statistically significant synergy was only
seen with CDDP and the platinum analogue JM40 in combinaton with IFN.
Improved activity with the addition of IFN was also seen with drugs
which were both active or inactive in these two xenografts (Table
6.1). Although as one would expect both NSCLC tumours were resistant
(SGD <1) to most agents. No attempt was made to explore the precise
mechanism of IFN potentiation of chemotherapy in these experiments.
This work is covered in Chapter 9.
The enhanced activity seen with the combinations of chemotherapy
and IFN described here comfirms previous reports using this form of
treatment in murine and human tumour models (Table 3.5). This effect
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has not previously been reported in human non-small cell lung cancer.




Activity of IFN/drug combinations in SCLC xenografts
7.1 Introduction
This section is similar to Chapter 6 in that it deals with the
activity of IFN/drug combinations in the xenograft model. After
showing significant potentiation of the activity of certain agents by
the addition of IFN in NSCLC tumours, it seemed important to try
these combinations in SCLC xenografts. SCLC is a more chemosensitive
disease than NSLC with chemotherapy being the treatment of choice in
the majority of patients.
Two human SCLC xenografts were used for testing IFN/drug
combinations, NX004 and WX322. Both were obtained from subcutaneous
deposits of patients with metastatic SCLC. Similar experimental
methods were employed for drug testing, with cytotoxic agents being
given in sub-optimal doses at regular intervals and IFN being given
daily at a low dosage level. Assessment of activity was as described
previously. Drugs with known clinical activity in SCLC patients were
assessed initially rather than merely repeating the same drugs used
in Chapter 6.
As SCLC xenografts are generally more chemosensitive than NSCLC
tumours it was considered to be important to perform full
dose-response evaluations for each agent, including IFN, prior to
testing combinations. This would enable more rational drug dosing
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with combination therapy avoiding the use of a dose of drug that
"cured" tumours as a single agent, leaving no room for improvement
with combination therapy.
7.2 Dose-response effect of IFN in NX004/4
Three different doses of IFN-alpha were assessed in this tumour:
2 x 10^ units/day, 5 x 10^ units/day and 2 x 10^ units/day. All were
given subcutaneously for 35 days at a site distant to the tumours.
The results of this treatment are shown graphically in Figure 7.1.
Control tumours doubled in 7 days. No effect on tumour growth was
seen with any dose of IFN. This experiment had to be terminated on
day 26 as many of the tumours were considered to be too large for the
host animal (6 x original volume).
7.3 Dose-response effect of CY in NX004/2
Four different doses of CY were assessed: 50mg/kg, lOOmg/kg,
150mg/kg and 200mg/kg. Each was given i.p. divided into five equal
doses (i.e. 10, 20, 30 and 40mg/kg) at weekly intervals on days 0, 7,
14, 21 and 28. The results are shown in Figure 7.2. Control tumours
had a median doubling time of 9 days. A total dose of 50mg/kg and
lOOmg/kg had no effect (median TD 8.5 and 10 days respectively). The
tumours in the groups treated with 150mg/kg and 200mg/kg remained
static during the 35 days of treatment. 3 tumours doubled in the
150mg/kg group (at 29, 29 and 31 days) and 2 tumours doubled in the
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200mg/kg group (both at 27 days). The same number of tumours in each
group regressed completely. No animals died in either group. There
was no evidence of toxicity in the 200mg/kg group.
7.4 CY/IFN combination in NX004/4
CY was given as 30mg/kg i.p. at weekly intervals. IFN was given
in the usual schedule. The growth of tumours in each group is
outlined in Figure 7.3. Control tumours doubled in a median of 8
days. IFN alone had no effect. CY at this dose gave similar results
to those seen in the dose/response experiment with most tumours
remaining static. The addition of IFN did not influence the activity
of CY (p>0.1).
7.5 Dose/response effect of ADR in NX004/4
As with CY, 4 different doses of ADR were assessed: 6, 8, 12 and
18 mg/kg. Each was given i.p in five divided doses at weekly
intervals. The results are shown in Figure 7.4. Control tumours
doubled in 9 days. Treatment with ADR at any dosage had no effect on
the tumours. The group receiving 12mg/kg appeared to have some
retardation of growth late in the experiment although this may have
reflected drug toxicity. All animals in the I8mg/kg group died
although this treatment had no effect on tumour growth. This tumour


























Figure 7.4: ADR dose/response experiment in NX004/4
7.6 ADR/IFN combination in NX004/5
ADR was given in a total dose of 12mg/kg. IFN was given in the
usual schedule. The results of single agent and combination
treatment are shown in Figure 7.5. Control tumours doubled in 7
days. ADR alone had similar activity to that seen in section 7.5
(median TD = 8 days). IFN alone had no effect. ADR in combination
with IFN had no effect on this tumour (median TD = 7 days). An
antagonistic effect was not seen (p>0.1).
7.7 Dose/response effect of Etoposide in NX004/2
Four different doses of etoposide were assessed (20, 35, 50 and
75mg/kg i.p. in five divided doses at weekly intervals). The results
are shown in Figure 7.6. Control tumours doubled in 9 days. As with
ADR, no dose of etoposide influenced the median doubling time of
tumours from their original volume. The two groups receiving 50 and
75mg/kg appeared to demonstrate an effect after the first three doses
(SGDs calculated from Tt = 0.23 and 0.3 respectively). However all
animals receiving a total dose of 75mg/kg died. This tumour appeared
to be resistant to etoposide.
7.8 Etoposide/lFN combination in NX004/5
Etoposide was given in a total dose of 45mg/kg. IFN was given
in the usual schedule (2 x 10^ units/mouse/day). The results are
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Figure 7.5: ADR/IFN combination in NX004/5
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Figure 7.6: Dose-response effect of etoposide in NX004/2
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shown in Figure 7.7. Control tumours doubled in 7 days. Etoposide
as a single agent had no significant effect (median TD = 8 days, SGD
= 0.14). The addition of IFN to etoposide did not influence its
activity (median TD = 7 days), indeed tumours in the combination
group appeared if anything to grow quicker than controls although
significant antagonism was not seen (p>0.1).
7.9 CDDP/lFN combination in NX004/6
A full dose/response experiment was not performed for CDDP in
this tumour. CDDP was given in the same schedule described for the
NSCLC xenografts i.e. 1.4mg/kg x 5 at weekly intervals. Control
tumours had a median TD of 7 days. IFN alone had no activity (median
TD = 7 days). Of the seven tumours treated with CDDP alone, 3
regressed completely and four doubled in size (in 7, 9, 13 and 28
days). The median TD for the CDDP/lFN combination group was 7 days,
the same as the controls and IFN as a single agent. This represented
significant antagonism between IFN and CDDP (F=5.1, p=0.03)
7.10 CY/IFN combination in WX322/4
The dosage schedules for this combination experiment were
identical to those outlined for NX004 in section 7.4. The control
tumours doubled in 11 days. IFN alone had no effect. Tumours
treated with either CY or CY and IFN remained fairly static in volume
with no difference between the two groups. Unfortunately after
approximately 28 days the majority of animals in these two groups
developed signs of infection with wasting and rapid breathing. Equal
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Figure 7.7 Etoposide/lFN combination in NX004/5
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numbers of animals were affected in the two groups concerned. This
was the last experiment performed (April 1986) prior to the serious
infection described in section 5.4.
7.11 Etoposide/lFN combination in WX322/4
The dosage schedules for etoposide and IFN were as oulined for
NX004 in section 7.8. Etoposide was given as 9mg/kg i.p. x 5.
Control tumours doubled in 15 days. Etoposide alone had significant
activity (median TD = 32 days, SGD = 1.13) with two tumours out of
nine remaining static. When the drug was given in combination with
IFN it appeared less potent (median TD = 20 days, SGD = 0.33) with
one tumour remaining static. This was an additive result (F=1.28, p
= 0.27)
7.12 Discussion
This section has assessed the effect of combining IFN with four
different drugs (CY, ADR, Etoposide and CDDP) in two SCLC xenografts.
IFN alone had no effect on the growth of either tumour. On no
occasion was the activity of a drug enhanced by the addition of IFN,
indeed in many cases the IFN/drug combination appeared less effective
than the drug as a single agent, suggesting a negative interaction.
However, only one combination (IFN and CDDP in NX004) showed
significant antagonism. These data are in marked contrast to the
experimental results described for the two NSCLC xenografts in
chapter 6.
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The two SCLC tumours used were more sensitive to certain agents
(CY, etoposide in WX322 and CY, CDDP in NX004) than NX002 and CX1L7
with single agent treatment sometimes causing complete stasis in
growth of the xenograft. However it should be noted that NX004 had a
rather unusual sensitivity pattern, being sensitive to CY and CDDP
but relatively resistant to ADR and etoposide. WX322 appeared a more
chemosensitive tumour but overall in both tumours IFN was unable to
improve on single agent drug activity whether the xenograft was
sensitive or resistant to the drug in question.
It is unclear why IFN/drug combinations appear more active than
single agents in NSCLC but not SCLC tumours. The dose and schedules
of administration for each agent were identical and the xenografts
were grown in the same type of host. Presumably therefore it must
reflect a fundamental biological difference between the two tumour
types.
It is not known why in the clinical situation small cell tumours
are generally more sensitive to chemotherapy and irradiation than non
small cell tumours. The fact that IFN can interact synergistically
with certain drugs in NSCLC xenografts but antagonistically with the
same agents in SCLC xenografts may help to shed light on important
differences between the two histological subtypes of lung cancer.
However this may not be possible until the exact mechanism by which





The concept of combining IFNs with other anti-cancer treatment
modalities has generated much interest both in the laboratory and
clinic (Section 3.3). Many combinations of different IFNs and
anti-cancer agents have been assessed using pre-clinical models and
pilot studies are underway to test these treatments in patients.
Unfortunately little attention has been paid to defining the optimum
dosage schedules for administering these combinations and many
different regimes are being assessed.
Laboratory data (Aapro 1983, Balkwi11 1982, Welander 1985)
suggest that IFNs have most anti-tumour activity when administered in
a chronic schedule, but this method of treatment may not be optimal
for cytotoxic drugs.
The experiments reported in this chapter were designed to try to
establish the optimum method for administering IFN in combination
with a cytotoxic agent using a combination studied in chapter 6 (IFN
and CDDP in NX002 - Section 6.2). Both the influence of dose and
schedule for each agent was assessed as well as the possible benefits
of pretreating tumours with IFN prior to the administration of CDDP.
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8.2 Methods
Drug testing was performed as described before. Groups of 8-10
tumours were stratified for size and randomly allocated to treatment
or control groups. Treatment activity was expressed in terms of the
specific growth delay where possible. Statistical analysis was as
stated in chapter 4. These studies were performed between the 15th
and 19th passages of NX002. The effect of different dosage schedules
for each agents in the IFN-CDDP combination was assessed as follows:
(i) IFN-<^2b (2 x 10^ units/mouse/day) was given s.c. for 35 days in
combination with the maximum tolerated dose of CDDP (7mg/kg) given
i.p. as either 1.4mg/kg x 5 (on days 0,7,14,21 and 28) or 3.5mg/kg x
2 (on days 0 and 10) or as a single 7mg/kg dose on day 0.
(ii) CDDP (1.4mg/kg x 5) was given in combination with three
different doses of IFN (5 x 10^, 10^ or 2 x 10^units/day) given s.c.
for 35 days.
(iii) The effectiveness of pretreatment with IFN followed by
treatment with CDDP alone was compared with simultaneous treatment
with both agents. The design of the treatment grouDS is shown in
Figure 8.1. One group received IFN (2 x 10 units/day) for 3 days
before a single 5mg/kg dose of CDDP. A second group was given the
two treatments simultaneously from day 0 to day 10. A third groun
received the same combination treatment after 3 days pretreatment
with IFN. Treatment activity was assessed by comparing the mean
tumour volumes and percentage increase in volume at days 0 and 10
rather than measurement of the SGD. It was felt that measurement of
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(i) Different doses and schedules of CDDP The results of these
experiments are summarised in Table 8.1. Control tumours had a
median doubling time of 8-12 days. IFN alone at this dose again had
no activity (SGD<0.2). The addition of IFN enhanced the activity of
all three doses of CDDP with the maximum effect being seen with the
middle dose (3.5mg/kg x 2). In this group no tumour doubled in size
(SGD for CDDP alone = 4.25). A single high dose of CDDP was least
effective (SGD for combination = 3.1, for CDDP alone = 2.8). The
interactions with CDDP 1.4mg/kgx5 and 7mg/kgxl appeared additive
(F<2, p>0.l) with the middle dose showing a positive interaction
(F=5.28, p=0.03). However meaningful comparisons between these
groups were impossible as the experiments were performed at different
times.
(ii) Different doses of IFN The results of these experiments are
summarised in Table 8.2. Control tumours had a median doubling time
of 8 days. CDDP alone (1.4mg/kg x 5) caused a prolongation of median
doubling time to 14 days (SGD = 0.75). This effect was enhanced by
the addition of all three doses of IFN. However statistically
significant interactions were not seen. The middle dose of IFN (lO"'
units/mouse/dav) appeared to be the most effective when combined with
this dose of CDDP (SGD increasing from 0.75 to 7.0). The activity of
IFN alone at these doses was not assessed but from previous work
(Carmichael 1986), the highest dose given here (2 x 10^
units/mouse/day) resulted in a SGD of 0.34.
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Median doubling SGD Regressions Static
Times (days)
Controls 9
CDDP IFN 10 0.11
1.4 mg/kg x 5
CDDP 17 0.88
CDDP + IFN 27 2.00
Controls
CDDP IFN
















* Calculation of doubling time and SGD impossible in this group as no
tumour doubled
TABLE 8.1: The effect of three different schedules of CDDP alone and
in combination with a fixed dose of IFN (2x10 unit/mouse/day for 35
days). Experiments performed once on separate occasions.
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Median Doubling SGD Regressions Static
Time (days)
Controls 8 -
CDDP alone 14 0.75 2
CDDP + IFN (5 x 104u/day) 43 4.3 1
CDDP + IFN (105u/day) 64 7.0 2 2
CDDP + IFN (2 x 105u/day) 48 5.0
Table 8.2: The effect of a fixed dose of CDDP (1.4mg/kg x 5 at
weekly intervals) alone and in combination with three different
doses of IFN. Experiment performed once.
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Meari Tumour Volume (cm )
DAY DAY DAY
-3 0 10
IFN CDDP .45 .58 .60
(129) (134)
CDDP + IFN .42 .60 .58
(140) (136)
IFN CDDP + IFN .44 .62 .55
(138) (124)




Influence of IFN pretreatment on IFN/CDDP combinations
Figures in brackets represent % increase from starting
volume on day -3. Experiment performed once.
in
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(iii) Pretreatment with IFN The results of these experiments are
summarised in Table 8.3. Control tumours grew steadily reaching 261%
of their original starting volume at the end of the study (14 days).
Pretreatment with IFN did not influence tumour growth from days -3 to
0. Sequential treatment with 3 days of IFN followed by 10 days of
CDDP was as effective in suppressing growth as 10 days of combination
treatment. Indeed no two groups were significantly different at the
p<0.05 level at any stage apart from at day 10 when all treated
groups were significantly different from controls (F=10.33,p<0.0001)
but not from each other.
8.4 Discussion
The results of these experiments indicate that both dose and
schedule can influence the activity of combination therapy with IFN
and CDDP in this tumour. Statistically significant interactions were
only seen once and the overall design of the experiments made valid
comparisons impossible. Larger experiments performed repeatedly are
required before firm conclusions can be reached. This may be best
done using an in-vitro model. The effectiveness of pretreatment with
IFN remains unclear.
Previous studies performed using animal models of human
cancer have shown that the administration of larger doses of IFN
results in greater inhibition of tumour growth (Balkwi11 1982, 1984,
We lander 1985, Carmichael 1986). A similar dose-response
relationship has been demonstrated in phase II studies of IFN therapy
in patients with Kaposi's sarcoma (Real 1984), renal cancer (Quesada
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1983) and mycosis fungoides (Bunn 1984). This effect presumably
reflects the direct cytotoxic actions of IFNs on tumour cells and may
not be relevant to IFN/drug combinations. Of the few reported
laboratory studies of IFN/drug combinations which investigated the
effect of dose of either agent, most found increased synergy at
higher dosage levels (Balkwill 1984, Purie 1986, Welander 1985).
However one group (Morris 1984), was only able to demonstrate
potentiation if low doses of IFN were used.
No in vivo studies have been reported which specifically
evaluate the importance of scheduling on the activity of IFN/drug
combinations. The results from in vitro testing suggest that
exposure to both agents over a prolonged time interval is important
(Aapro 1983, Welander 1985) and many of the clinical studies
currently assessing these combinations have attempted to achieve this
(Purie 1986, Green 1985). Certainly IFN and other biological
response modifiers as single agents are most effective both in the
laboratory and the clinic when given in a chronic schedule (Balkwill
1982, Spiegel 1985, Vaage 1987, Welander 1985).
Whether IFN and drugs in combination are best administered
concurrently or sequentially is unclear. Welander (1985) studied
this scheduling effect in vitro with a variety of drugs and cell
lines. Although positive interactions were observed when the two
agents were given sequentially, the most potent synergy was
demonstrated with combined continuous exposure. In the one
experiment reported here, no difference was seen between sequential
treatment with IFN and CPDP (i.e. 3 days IFN followed by 10 days
CPPP) and combined therapy (i.e. 10 days COBP + IFN). Unfortunately
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it was not possible to include a group treated with CDDP alone to
ensure that a positive interaction between CDDP and IFN had occurred.
If no such interaction had occurred, then the activity seen with both
forms of treatment would merely reflect 10 days of CDDP treatment
(since IFN alone has no effect) and would obviously cause similar
delay in growth with each group. Data from experiments in Chapter 6
would suggest that it may take at least 10 days of combined treatment
with IFN and drugs before significant synergy can be appreciated.
Clearly this makes the results of these experiments investigating the
effect of three days pretreatment with IFN difficult to interpret.
What is the relevance of this work to the design of clinical
trials? A major factor preventing the prescribing of IFN/drug
combinations on a rational basis lies in the fact that the precise
mechanisms of synergy between the two agents is poorly understood.
Many of the cellular effects of IFN have a complex dose-response
relationship and some (e.g. NK cell activity) may even be inhibited
in patients at higher doses (Edwards 1985). Another potential
problem in the design of IFN/drua combinations may lie in the fact
that individual patients have been shown to exhibit totally different
degrees of tissue responses (e.g. modulation of 2-5A synthetase) to
the same dose of IFN (Merritt 1986). Until more is known about the
precise mechanisms of the interactions between IFN and cytotoxic
drugs, the design of relevant clinical studies will remain difficult.
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CHAPTER 9
Possible Mechanisms of Synergy
9.1 Introduc t ion
The results obtained in Chapter 6 have suggested that an
interesting interaction occurs between interferon and certain
cytotoxic agents when tested against human NSCLC xenografts in mice.
Whilst other workers have reported similar results in other test
systems (Chapter 3), little attention has been paid to explaining why
such synergy may occur. Most reports comment on the many different
actions of IFNs on tumour cells and host responses and are eager to
point out the possible clinical potential of combining IFN and
cytotoxic agents. In the scope of this project it was not felt
possible to investigate these mechanisms in detail. However two sets
of experiments were performed.
One possible explanation for the apparent increase in the
activity of cytotoxic drugs in animal experiments may be that IFN
potentiated the toxicity of the drugs to the host and subsequent
tumour shrinkage was due to ill health in combination treated groups.
To assess this, we have measured the body weight of mice undergoing
combination treatment for 35 days as an assessment of animal health
and compared these mice with control and single agent groups.
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Secondly we have assessed the possible influence of cell cycle
effects in IFN/drug combinations as in the one reported study which
looked at possible mechanisms of interaction (Balkwill 1984a), these
effects appeared to be important.
9.2 Body weight study
(i) Methods Clearly it was important to investigate a
combination where positive interactions were seen. Treatment with IFN
and cyclophosphamide in CX117/10 (section 6.6) was selected. Groups
of 6-8 tumours (5-6 animals) were randomly allocated to either a
control group, to receive cyclophosphamide 40mg/kg i.p. at weekly
4
intervals, IFN 2 x 10 units/mouse/day s.c. daily for 35 days, or to
a combination group. Animals were weighed each week and the lean
body weight was calculated by subtracting the weight of the
tumour(s). This was estimated using the correlation between tumour
size and weight shown in figure 5.1. This correction prevented an
overestimation of body weight in control animals with growing tumours
and a possible false weight loss in animals whose tumours were
smaller because of treatment.
(ii) Results These are shown in figure 9.1. The mean weekly
weight of control animals increased steadily through the four week
period. No significant difference was seen in the mean weekly weight
of the other three groups. Treatment with IFN and cyclophosphamide
was certainly not associated with weight loss when compared to
cyclophosphamide alone. The animals in both these groups appeared




gure 9.1: The effect of single agent and combination treatment with
cyclophosphamide (CTX) and IFN on mean body weight in CX117/10
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related to intercurrent infections) did occur in all the xenograft
experiments (see section 5.4) an excess of deaths or increased ill
health was not seen in groups of animals treated with combination
therapy compared to single agent treatment. It can be concluded that
any enhancement of cytotoxic drug activity by IFN in xenografts is
not mediated through increased toxicity to the host animal.
9.3 Cell cycle effects
In vitro studies have demonstrated that IFNs are capable of
increasing the length of all phases of the cell cycle in malignant
cells (Balkwi11 1978). Many cytotoxic agents are known to be more
effective in specific phases of the cell cycle and therefore it is
possible that IFNs may potentiate a eyele-specific drug by increasing
the number of cells in a certain phase. We have studied the effect
of drug and IFN treatment on the cell cycle of tumour cells taken
from xenografts treated with two combinations, one where a positive
interaction occurred and one where no such interaction was seen.
(i) Methods
Two drug/lFN combinations were assessed: CDDP and IFN in NX002
(section 6.2) and CYCLO and IFN in NX004 (section 7.4). The doses
used were identical to those used in the original experiments. Ten
animals were included in each group. Two animals were sacrificed on
day 0 (pretreatment) and then each day until day 4 after treatment.
IFN was given daily to the surviving animals in the IFN and
combination groups in the study. The drugs were given once on day 0.
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Cell suspensions were prepared using the method described by
Martens (1980). Briefly, the tumours were removed and chopped finely
with crossed scalpels in RPM1 1640 medium. The suspension was shaken
2
and gently pipetted through a 100 ura nylon mesh. The resulting
suspension was spun down at lOOOrpm for 5 mins and then resuspended
in Hanks' buffered salt solution containing lOmM HEPES. The cells
were then centrifuged for 10 mins at 400g and resuspended in
0.9%NaCl. They were then added dropwise to twice the volume of 96%
ethyl alcohol at -20°C. The samples were then stored at 4°C for
later use.
DNA staining was performed on the entire batch of samples prior
to fluorescence measurement. Cells were taken from the pellet,
£
adjusted to a concentration of 1 x 10 cells/ml and spun down at
lOOOrpm for 5 minutes. Cells were resuspended in 1 ml of staining
mixture comprising 0.005% propidium iodide in 0.1% sodium citrate in
the presence of 0.1% triton X. This stain was stable for 2-3 hours.
Cells were analysed with a FACS-II cell sorter (Becton
Dickinson, Sunnyvale, Ca) using a 488mm argon laser. The percentage
of cells in each phase of the cell cycle was analysed from the
resulting histogram printout using the mathematical model of Dean
(1980). The mean % values of different groups at any one time were
compared by analysis of variance.
(ii) Results
The changes in cell cycle distribution during the first four
days of each treatment regime is illustrated in Figures 9.2 and 9.3.
In NX002 where a positive interaction occurred between IFN and CDDP
little change in cell cycle distribution was seen in any group. IFN
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Figure 9.3: Changes in cell cycle distribution in NX004 after IFN/CY
therapy
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cycle. In both the CDDP and the CDDP/IFN groups there was a small
rise in the percentage of cells in G2 on days 3 and 4. There was no
difference between these two groups.
In NX004 where no interaction between CY and IFN was seen, more
marked changes were seen reflecting the influence of CY on the cell
cycle distribution. IFN alone had no effect compared to controls.
In the CY and CY/IFN groups an immediate increase in the percentage
of cells in the S phase was seen. This was followed 24 hours later
by a sharp rise in the proportion of cells in G2. Although this
effect was perhaps more marked in the CY alone group, no significant
differences between these groups were seen. There was certainly no
early and sustained rise in S phase cells in the combination group
which has been reported by Balkwill (1984a).
9.4 Discussion
It is likely that interactions between IFN and chemotherapeutic
agents are complex. There may be direct interactions between the
drugs and IFN on tumour cells or indirect effects of IFN on drug
metabolism or host defences. All these mechanisms have been
postulated in previous studies of IFN/drug combinations.
Aapro (1983) showed synergistic effects between the vinca
alkaloids and leucocyte interferon in a clonogenic assay and
hypothesised that this may have been the result of the known effects
of vinblastine on tubulin and the action of IFN on the cyto-skeleton.
As well as suggesting that phase I-II clinical trials should be
started, they also conceded that "mechanistic studies would be needed
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to delineate the nature of the potentiating drug interaction".
Saito (1987) studied IFN gamma and various drugs in a similar
assay system. By introducing macrophages from malignant effusions
they showed a potentiation of the activity of IFN gamma alone as well
as in combination with doxorubicin. However the efficacy of the two
agents was never more than additive. The role of macrophages in the
efficacy of cytotoxic drugs is poorly understood. Colotta (1986) has
shown that the combination of cytotoxic agents and macrophages
enhances the susceptibility of tumour cells to macrophage killing.
The demonstration of this effect required direct contact of the
macrophages with the tumour cells. As it is well known that IFNs
(especially IFN-gamma) are capable of activating macrophages for
tumour cell killing (Pace 1983, Schultz 1978, Svedersky 1984) this is
a possible mechanism by which IFNs and drugs could interact
synergistically. However, IFN gamma has shown little such potential
in assay systems compared to IFN alpha and it would not explain why
positive interactions have been seen in-vitro in the absence of
tumour associated macrophages.
It seems more likely that IFNs and drugs interact directly on
tumour cells. This was certainly the conclusion of the one elegant
study (Balkwill 1984a) which has investigated this effect in some
detail. The authors had shown previously (Balkwill 1984) that human
IFN potentiated the effect of adriamycin and cyclophosphamide in a
human breast carcinoma in nude mice. They then showed that human IFN
did not affect hepatic levels of key drug metabolising enzymes
whereas murine IFN did. The addition of murine IFN to the human
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IFN//drug combinations had no effect on the final result and did not
increase the toxicity of the combination therapy. They concluded that
the increased activity of the combination was due to effects on the
tumour rather than the host. Additional studies investigating the
effect of this treatment on cell cycle distributions suggested that
IFN, which alone had little effect on the cell cycle, appeared to
increase the number of cells in S phase when given with
cyclophosphamide or adriamycin. This did not happen with CY or ADR
alone. They hypothesised that since both drugs would be more active
against cells actively synthesising DNA, the S phase accumulation
seen in the combination therapy groups was responsible for the
enhanced cytotoxicity.
In our brief studies in this section, we have shown that any
potentiation of alkylating agents by IFN is not mediated through
increased toxicity to the host animal. This would certainly explain
why synergy has been clearly demonstrated in vitro. Like Balkwill we
have shown that IFN alone has little effect on cell cycle kinetics.
We have shown like others (Balkwi11 1984a, Barlogie 1978) that
treatment with CY is associated with an induction of G2 phase arrest.
Unlike Balkwill, we have not shown that the addition of IFN delayed
this G2 block and increased the number of cells in S phase. However
since this combination was not synergistic in this tumour we cannot
rule out this effect as a possible mechanism of interaction in other
systems.
CDDP is thought to exert its cytotoxicity by forming interstrand
and intrastrand crosslinks in tumour cell DNA and although the
specificity of CDDP with regard to the phase of the cell cycle
appears to differ among cell types (Zwelling 1982), the effects on
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cross-1inking are most pronounced during the S phase. In our studies
neither CDDP, IFN or the combination had any significant influence
on cell cycle distribution of a tumour where positive interactions
were seen. We must therefore conclude that although it is likely
that these effects are mediated directly on the cell, modulation of
cell cycle distribution is not the sole mechanism involved.
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Summary
The experiments reported in this section have demonstrated that
potentially important interactions between IFN and cytotoxic agents
can occur. Synergy was seen between various cytotoxic agents and low
doses of alpha IFN in NSCLC xenografts with the most marked effect
being seen with CDDP and platinum analogues and IFN. No such effect
was seen with various drugs and IFN in two SCLC tumours and indeed
there was some evidence that antagonistic interactions had occurred.
The section on dosage and scheduling was unhelpful and requires
repeating perhaps using an in-vitro model. More studies
investigating the precise mechanisms of these interactions may be
required before these combinations can be properly exploited in a
clinical setting.
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In Section II the activity of combination therapy with
interferon alpha and various cytotoxic agents was studied in vivo
using human lung cancer xenografts. This system allows for drug
testing on solid tumours in a physiological 'environment' but complex
variables such as tumour vascularity, host rejection responses and
drug penetration and kinetics can make interpretation of drug
activity difficult. This is especially true when biological response
modifiers are being assessed. In this section an attempt was made to
measure direct cytotoxic effects by testing these combinations
against lung cancer cells in vitro.
In order to try and make direct in vivo/in vitro comparisons
assays were attempted on cells taken from the xenografts tested ir.
Section II. In vitro assessments of drug/lFN combinations were also
performed using human lung cancer cell lines established in other
centres. In one of these cell lines (A549) a xenograft line was
established in the thymectomised, irradiated mouse model to allow
further in vitro/in vivo comparisons.
Two types of clonogenic assay were performed to assess treatment
activity. In the cell lines which grew as floating aggregates and
-157-
for cell suspensions prepared from xenografts, a soft agar (Courtney)
assay was used. In the cell lines which grew as an adherent
monolayer, a simple 'plastic' cloning assay was used.
10.2 The Courtney Assay
This assay system measures the effect of treatment with
cytotoxic agents on the cells within a tumour which are capable of
forming a clone and repopulating the tumour (the 'stem cells'). The
percentage of these cells within a tumour may be low and the cloning
efficiency may be further reduced by cell damage during
disaggregation and the inadequacy of culture conditions. The
Courtney soft agar system represents an attempt to improve the
plating efficiency of tumour cells by simulating more closely growth
conditions in vivo.
Cells are cultured in a low oxygen concentration to provide a
more physiological oxygen tension in the medium and the addition of
rat red blood cells supplies labile growth factors lacking in
standard culture media. The detailed methodology is as follows:
10.2 (a) Preparation of cell suspensions
Xenografts were removed using sterile techniques and placed in
chilled RPMI medium prior to transfer to the laboratory. Non-viable
tissue was then removed by dissection and the remaining tumour
fragments transferred to a fresh petri dish. The tumour tissue was
then disaggregated using crossed' scalpels into a broth. This was
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then passed through a N100 nylon mesh filter, transferred to a
universal container and then spun at 2,000 rpm for 6 minutes. The
supernatant was removed and the cell pellet resuspended in fresh
medium. A single cell suspension was then made by flushing this
preparation five times through a 19G needle. Cell numbers were then
counted using a haemocytoraeter with viability being estimated by
nigrosin exclusion. Suspensions were diluted with culture medium to
5 x the required final concentration.
When this assay was used in cell lines which grew as floating
aggregates (H69 and WX322) less disaggregation was required. A small
aliquot (2-5mls) of medium and cells was taken from the culture
flask. A single cell suspension was obtained by flushing through a
21G needle. Cell numbers were counted using a haemocytometer and
viability assessed using nigrosin exclusion. The suspension was
diluted to 5 x the required final concentration with culture medium.
10.2 (b) Preparation of rat red cells (RBCs)
Adult male and female August rats were obtained from Bantin and
Kingman (Hull). Animals were anaesthetised with ether and laid
supine. The fur on the anterior chest wall was soaked with ethanol.
Blood was withdrawn by cardiac puncture into a sterile syringe
containing a small quantity of preservative-free heparin. The blood
was then ejected into a universal container and the level of the
meniscus marked. lOmls of PBS was then added. The blood was spun at
3,000 rpm for 15 minutes. The buffy coat was removed with the
supernatant and discarded. The RBCs were rinsed twice with PBS and
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th en resuspended to the original blood volume in RPMI medium. The
resultant sample was then heat inactivated for 1 hour at 44°c. RBCs
were stored for up to 1 month at 4°c.
10.2 (c) Assay procedure
RPMI 1640 medium supplemented with 10% foetal calf serum and
2.5mg/ml bovine insulin, lmM sodium pyruvate and MOPs were used in
all cultures. Tumour cell cultures were diluted to 5 x the required
final concentration. Rat RBCs were diluted 1:8. Drugs were made up
in PBS and diluted to 10 x the required final concentration. 5% agar
solution was sterilised in a pressure cooker and then diluted with
warmed medium to make a 0.5% agar solution (2mls of 5% agar and I8mls
medium).
To set up 5 replicate tubes for a single drug concentration the
following was measured out into a glass universal container and kept
at 37°:
1.2mls of tumour cell suspension
0.6mls of rat RBCs
0.6mls of drug or control (PBS)
3.6mls of freshly prepared 0.5% agar medium was quickly added to make
up to 6mls (0.3% agar). This was rapidly mixed by inversion and then
using a pastette 1ml aliquots were pipetted into 5 Falcon tubes
before the agar could set. The tubes were then placed in ice for 5
minutes to allow the agar plug to form.
Treated and control tubes were then placed in a rack and
incubated in a Hereans incubator at 37°c, 100% humidity, 5% Co^, 5%
0? and 90% N After 7 days, 1 ml of culture medium was gentle
-160-
pipetted on top of the agar plug. This was repeated at 14 days. At
21 days, 1 ml of "old" medium was carefully withdrawn and replaced
with 1 ml of fresh medium.
Colony counting was performed at approximately 21-28 days.
Medium was discarded using a pastette. The agar plug was decanted
onto a 5cm petri dish lid and squashed flat with a grided dish to
facilitate counting. Colonies of more than 50 cells were counted
under an inverted microscope. Drug activity was calculated from the
number of colonies surviving treatment compared to controls and
expressed as a percentage.
10.3 The plastic cloning assay
Drug activity could be rapidly assessed in cell lines which grew
as adherent monolayers (A549, H125, H23) by using a plastic cloning
assay. In principle the assay is similar to the Courtenay assay but
agar support and extra nutrients are not required.
A major advantage of this system is that since the cells grow
adherent to plastic it is possible to change the culture medium at
any time. This allows for cells to be exposed to cytotoxic agents
for set time periods (e.g. 1 hour, 24 hours, 5 days etc.) and for
scheduling of drug combinations into sequential or concurrent
exposure.
Cells were harvested from culture flasks by a short exposure to
0.2% trypsin and 0.02% versin. A single cell suspension was made by
flushing the suspension through a 19G needle. Cell numbers and
viability were assessed with a haemocytometer using nigrosin
exclusion. The cells were then carefully pipetted into 6 well
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costar plates (2mls/well), the final concentration of the suspension
being adjusted in light of the plating efficiency to allow
approximately 100 colonies to grow in each well. The plates were
then incubated at 37° for 24 hours to allow the cells to attach. The
following day all medium was carefully removed from each well with a
pastette and replaced with 2ml of fresh medium containing the drug
being tested in the required concentration. Control plates were
treated with fresh medium alone. Each drug concentration was
performed in triplicate.
Cells were returned to the incubator and left undisturbed. The
medium was changed and drug removed at the appropriate time if
limited exposure was required. In general, colony counts were
performed after 5-7 days. Medium was removed by pastette and the
remaining cells were washed in PBS, fixed with methanol/acetone (1:1)
and stained with haematoxylin. Colonies of >32 cells were counted
using an inverted microscope and drug activity expressed as the
percentage colony survival compared to controls. All assays were
performed in triplicate to ensure uniformity of results.
10.4 Drug/IFN scheduling
The cell lines used for combination testing in vitro are shown
in Table 10.1. To enable the correct interpretation of the
interactions between agents, full dose-response experiments for each
agent were performed prior to combination therapy. This allowed
selection of an appropriate dose for each agent in the combination.
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Designation Cell Type Source
Courtenay Assay
NCI-H69 Small cell Prof. A Harris (Newcastle)
A549 Adenocarcinoma Prof. A Harris (Newcastle)









Prof. A Harris (Newcastle)
Dr. S Merry (Glasgow)
Dr. S Merry (Glasgow)
Table 10.1 Cell lines used in in vitro assay
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Human recombinant IFN- 2b (Sobering Corporation, Bloomfield N.J.)
was diluted in culture medium and tested over a range of
concentrations (1-10 units/ml). Two cytotoxic agents, CDDP (Bristol
Myers, Slough) and adriamycin (Farmitalia Carlo Erba, St. Albans),
were used as single agents and in combination with IFN. Drug
8 ~6 g
concentrations over the range of 10 to 4x10 M(CDDP) and 5x10 to
2x10 ^M(ADR) were used.
In the Courtenay assays CDDP only was used in combination with
IFN. Cells were treated continuously with each agent. No attempt
was made to pretreat with IFN and drugs and then remove these agents
prior to plating out in agar. In the plastic assays, combinations of
IFN and both drugs were tested. Exposure of cells to agents for 24
hours and 5 days were performed.
10.5 Statistical analysis
Single agent dose response experiments showed that both ADR and
CDDP had non linear curves in most experiments. The validity of
merely multiplying the effects of each agent in a combination to get
the expected interaction result would appear to be questionable as
discussed by Steel (1979). He suggested a complex "isobole" method
of assessing interactions between two agents with non-linear
dose/response curves and this type of analysis was therefore
undertaken. Unfortunately this method does not allow for any
statistical consideration of the data in terms of assessing the
significance of any interations seen.
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Expert statistical advice was obtained and it was decided to
test the significance of any effect of different agents both singly
and in combination by analysis of variance with the data transformed
to loge«
The Student-Newman-Keuls procedure was used for single agent
activity, with interactions between combinations of IFN and drugs
being assessed by 2-way analysis of variance using a factorial
design. The null hypothesis was that interactions were additive and
this allowed for separations into significant synergy or antagonisms
(supra- or sub-additivity as described by Steel).
10.6 In vitro/In vivo comparisons
Direct in vitro/in vitro comparisons were attempted when
drug/lFN combinations were studied in cells taken from the xenografts
NX002 and WX322. The adenocarcinoma cell line A549 was established
as a xenograft by injecting a cell suspension (>10^ cells in 0.5ml)
s.c. into the flank of a thymectomised, irradiated CBA mouse. This
4
allowed drug testing in vivo. CDDP (3.5mg/Kg x 2) and IFN (2 x 10
units/day) were given as single agents and in combination in groups
of tumour bearing mice using the typical schedules described in
Chapter 4. Treatment activity was assessed using the specific growth
delay and compared to the results of the same treatment applied to





Attemps made to perform assays on xenografts taken directly from mice
were unsuccessful. This was in part due to an extremely low plating
efficiency and presumably due to special cultural requirements, since the
small number of colonies that would form did not show progressive growth.
Assays were performed on the SCLC xenograft WX322 after it was established
as a cell line. The majority of Courtenay assays were thus performed on
the established cell lines A549 and H69.
(i) A549 This cell line had a plating efficiency of approximately 1% in
agar which allowed for easy testing. The effect of IFN and CDDP as single
agents is shown in Figure 11.1. Combination experiments were performed on
separate days from the single agent experiments. Marked inter experimental
2
errors were seen (10 u/ml of IFN caused 65% and 22% on separate days).
When the two agents were given in combination a sub-additive interaction
was seen. (Appendix - isobologram 1). However this was not statistically
significant (F=2.3, p=0.15).
(ii) H69 The plating efficiency in agar of H69 cells was approximately 5%.
The effects of IFN and CDDP as single agents are shown in figure 11.2.
When compared to A549 cells, CDDP had similar activity (IC,_q0.3uM) but IFN
was less effective approx 10^units/ml) with a flatter dose/response
curve. The isobologram showing the interaction between IFN and CDDP is
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Figure 11.3 Isobologram showing effect of IFN and CDDP in combination on H69
(Courtenay Assay). Doses of each agent converted to logarithms. The
isoeffect plot is drawn from single dose/response curves (for methods see
Steel 1979). The cross marks the observed effect from IFN/CDDP combination.
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/ 3
Two different doses of IFN (10 and 10 units/ml) and CDDP (luM and 0.5uM)
were tested. Although the isobologram of their combinations suggests
subadditivity, statistical analysis shows that an additive interaction
occurred (F = 0.4, p = 0.64).
(iii) WX 322 As with the other xenografts, attempts to perform Courtenay
assays with WX322 tumours direct from mice were unsuccessful. A continuous
cell line of WX322 growing as floating aggregates was eventually
established by Dr S Langdon. Courtenay assays have been performed with
these cells using both IFN and CDDP. Surprisingly the WX322 cell line
appears to be acutely sensitive to IFN with 10 units/ml causing a 90%
inhibition of colony formation and even 1 unit/ml having a significant
effect (16% inhibition). This sensitivity to IFN is not seen in vivo (see
section 7.10) and presumably represents an adaption to growing in vitro as
a cell line. This change in sensitivity precluded direct in vitro/in vivo
comparisons using WX322 and no in vitro combination studies were attempted.
The extreme sensitivity of this cell line to IFN is being further
investigated by Dr S Langdon.
11.2 Plastic Assays
The three adenocarcinoma cell lines A549, H125 and H23 were used to
assess the activity of two different schedules (24 hour and 5 day exposure)
of two drugs CDDP and ADR alone and with IFN in these assays. The plating
efficiencies of these well established lines were high (approx 30%).
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(i) 24 hour exposures
Single agent activity of 24 hour exposures of IFN, CDDP and ADR
expressed as the percentage survival for the three cell lines is
illustrated in Figures 11.4 to 11.6. The concentration of drug resulting
in 50% inhibition (IC^q) was similar for all three cell lines although H125
was generally more sensitive to ADR and CDDP that the other two lines. The
IC^pValues for IFN were also within a similar range. These figures are
shown in table 11.1. ^50 va^ues could not be calculated for IFN since no
concentration tested resulted in a 50% inhibition of colony formation. The
effect of combining either drug and IFN for 24 hours is shown as
isobolograms in Figures 11.7 to 11.9.
A549
Figure 11.7 shows the effect of combination treatment for 24 hours in
4
A549. The addition of IFN 10 units/ml made little effect on three different
doses of CDDP and ADR. These interactions appeared sub-additive on the
isobologram but statistically were additive (F = 1.0, p = 0.4 for CDD? and
F = 0.05, p = 0.76 for ADR). Similar results were seen with a smaller dose
3
of IFN (10 units/ml) which had little activity as a single agent. For
simplicity, these results have been recorded in the Appendix.
H 125
Figure 11.8 shows the effect of combination treatment for 24 hours in
H125. The results were similar to A549. In all doses the addition of IFN
4
(10 ) to both drugs gave more activity than seen with the drug alone but
the interactions seen although appearing subadditive on the isobologram,
were no more than additive (F = 0.0, p = 0.99 for CDDP and F = 1.9, p =
3
0.17 for ADR). A similar effect was seen with a lower dose of IFN (10 ).
For simplicity, these results have been recorded in the Appendix.
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A549 8 x 104 1.2 24
H125 7 x 103 0.48 10
H123 6 x 104 1.1 49
Table 11.1: values for single agents (24 hour exposure)
(plastic assay)
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Figure 11.9 shows the effect of combination treatment with a 24 hour
exposure in this cell line. Once again no positive interactions were seen.
The activity of CDDP was virtually unaffected by the addition of IFN. The
interaction was additive in nature (F=0.8, p=0.48). The results with ADR
were interesting with significant sub-additivity being seen (F=3.9,
3
p=0.045). Combinations using IFN at 10 units/ml were not assessed in this
cell line.
ii) 5 day exposures
Single agent activity of 5 days exposure to IFN, CDDP and ADR for the
three cell lines is illustrated in Figures 11.10 to 11.12. The 10,.^ ^^30
for IFN) values are shown in table 11.2. As expected the longer exposure
resulted in a greater inhibition of colony formation and lower values
than the 24 hour exposure. This was especially true for IFN. Once again
H125 was the most sensitive line to IFN whilst H23 was relatively resistant
to ADR compared to the other two lines. The effect of combining either
drug with IFN for a 5 day exposure is shown in figures 11.13 to 11.15.
A 549
Figure 11.13 shows the effect of combination treatment for 5 days in
A549. Similar results to the 24 hour exposures were obtained.
Statistically, the interactions betwen the agents were additive (F =2.3,
p=0. 12 for CDDP and F=0,6, p=0.454 for ADR). Further combinations with a
3
higher dose of IFN (10 units /ml) were also additive. This data is
presented in the Appendix for simplicity. The ADR/lFN combination appeared
less promising in a 5 day schedule although unfortunately only one dose of
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A549 2 x 102 0.08 5.0
H125 7 x 101 0.45 4.0
H23 8 x 102 0.54 27.0
Table 11.2: IC^q values for
(*IC3Q for I FN)
single agents (5 day exposure)
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H125
The effect of combination treatment with IFN and both ADR and CDDP for
5 days in H125 is shown as isobolograms in Figure 11.14. Again increased
activity for two agents was seen (especially at low drug doses) when
compared to the drug alone. This was an additive effect (F=2.64, p=0.06
for CDDP and F=0.8, p=0.5 for ADR). These results are similar to the 24
hour exposures.
H23
Figure 11.15 shows the results of 5 days combination therapy in this
cell line. Overall the results were similar to the other cell lines.
Additive interactions were seen between IFN and ADR (F=0.2, d=0.788). In
3
one combination (CDDP 0.25uM and IFN 10 units/1) there was an antagonistic
effect (F=4.1, p=0.02) but this was not repeated at higher doses of CDDP.
11.3 In vitro/in vivo comparisons
As stated above, attempts at establishing the xenografts as cell lines
or testing cells from xenografts directly in vitro have to date been
unsuccessful. WX322 has been grown as a cell line but its sensitivity to
IFN appears to have dramatically increased in the process making direct in
vitro/in vivo comparisons meaningless.
Successful growth of the adenocarcinoma cell line A549 as a
subcutaneous xenograft was achieved and combination therapy was assessed
after the third passage. Control tumours had a median TD of 13 days. The
group treated with interferon alone had a median TD of 19 days (SGD 0.46).
CDDP as a single agent had identical activity (median TD 19 days, SGD
0.46). Combination treatment resulted in median TD of 29 days (SGD 1.2)














Figure 11.15: Effect of CDDP/IFN and ADR/IFN treatment on H23
(5 day exposure)
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appeared to show additivty (F = 1.36, p = 0.4).
These results would appear to be comparable with the interactions seen
between CDDP and IFN against A549 cells in vitro for both the Courtenay
assay (Figure 11.1) and the plastic assays (Figures 11.7 and 11.13). These
short exposure in vitro experiments (24 hours) are less comparable to the
xenograft tests than the longer exposures on plastic or the Courtenay
assay. In vivo chronic exposure was achieved by divided doses of CDDP ten
days apart and daily injections of IFN.
11.4 Discussion
The experiments in this section have assessed the effects of combining
IFN with two drugs against human lung cancer cell lines using two in vitro
assay techniques. Two different exposure times were used in the plastic
assay and various doses of both drugs and IFN were tested. In all cases,
the interactions between the two agents were no more than additive.
Statistically significant sub-additivitv was seen twice in the H23 cells
with CDDP over 5 days and ADR over 24 hours. However as multiple
statistical tests were performed (3 cell lines, 2 exposure times, 3 doses
of 2 different drugs = 36 comparisons) one might expect two apparently
significant results to appear by chance (p>0.05) when in fact no actual
effect was present.
Positive interactions have been shown in vitro by other workers
(Welander 1985, Heston 1984, Gohji 1986, Rosenblum 1984, Ho 1985,
Hirabayashi 1985, Aapro 1983) using a variety of assay systems and
different cell lines. Most workers have tested different drugs with
different IFN subtypes and a variety of different types of interaction from
obvious synergy to frank antagonism have been seen. Some (Saito 1987)
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have, like us, only shown additive effects. No pattern seems to be
emerging. No single drug appears to cause synergy consistently although
DFMO and the alkylating agents appear the most successful. Clearly not all
drug types are suitable for testing in vitro. In addition, no dosing
schedule appears more successful than others although chronic exposure
seems to be important.
Some of the studies above could be criticised in the method by which
the nature of any interaction was assessed. Many used the term "synergy"
to describe a response where the level of cell survival for the combination
was less than the product of the separate surviving fractions for each
agent alone. As pointed out by Steel and Peckham (1979) this
multiplicative method only holds if the dose-response curves for each agent
are linear (i.e. the agent is "additive with itself"). Most dose-response
curves are not linear. Only one other study (Gohji 1986) apart from
ourselves uses Steel's method of calculating additivity. They showed
definite evidence of synergy. Unfortunately this method does not allow for
measurement of the significance of any observed interaction and it was^for
this reason that the data here was subjected to an alternative statistical
analysis.
Only one study (Heston 1984) has attempted to make a direct in vitro/in
vivo comparison. They showed evidence of synergy in vitro but just
additive effects in vivo between DFMO and I FN— in a renal cancer cell
line. We showed similar additive interactions in vitro and in vivo between
CDDP and IFN in the lung adenocarcinoma cell line A549. It was unfortunate
that we were unable to assess an interaction known in be synergistic in
vivo using an in vitro assay. This would have enabled us to assess if the
interaction was mediated through a. direct effect on the tumour cells.
Attempts to establish these xenografts as cell lines are continuing.
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SECTION IV - CLINICAL STUDY
Chapter 12 - Evaluation of cisplatinum combined with
interferon-alpha in patients with NSCLC
12.1 Introduction
The aim of testing novel therapeutic strategies in
laboratory tumour models is to ultimately provide more effective
treatment for patients with cancer. It is surely only of
academic interest if a certain treatment is shown to be
extremely effective at killing tumour cells in culture or in
laboratory animals but is inactive in patients with similar
tumours. All promising advances in the laboratory must
eventually be assessed in a clinical setting both to validate
the pre-clinical testing system used and improve the outlook of
patients with hitherto untreatable conditions.
After obtaining the promising results described in Section
II of combination treatment with IFN and cytotoxic drugs in
NSCLC xenografts it was felt important to design a pilot
clinical study to assess this form of treatment in patients with
lung cancer. Since the most impressive synergy between the two
components of the combination was seen when cisplatinum was
used, it was decided to evaluate this combination initially.
Information gained from the scheduling experiments (Chapter 8)
was used in the design of the study. The objectives of the study
could be summarised as follows:
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1. To examine the anti-tumour activity of human recombinant
interferon alpha combined with CDDP in treating squamous,
large cell and adenocarcinoma of the bronchus.
2. To identify any factors associated with a response to the
treatment.
3. To document the toxicity associated with this treatment.
12.2 Selection of patients
Patients with histologically proven or cytologically
confirmed non-small cell carcinoma of the bronchus were
considered for the study. All patients had to have inoperable
but evaluable disease. The age limit for entry was 75 years.
All entrants required a performance status of 2 or less and a
life expectancy in excess of 12 weeks. Adequate renal and
hepatic function (serum creatinine <0.11mmol/l and bilirubin
<14mmol/l) were required as well as evidence of adequate bone
9
marrow reserve with white cell count greater than 3.5 x 10 /I
9
and a platelet count in excess of 150 x 10 /l.
A previous history of malignant disease apart from treated
basal cell and squamous carcinoma of the skin excluded patients
from the study. Previous surgery or radiotherapy made patients
ineligible unless there was documented evidence of progressive
disease at an untreated site. Previous chemotherapy excluded
patients from the study.
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12.3 Investigations and assessments
Standard UICC criteria were used to assess responses. The
investigations performed before entry into the study and prior
to each treatment course are outlined in table 12.1. Optional
investigations such as liver or bone scans, respiratory function
tests, bone marrow examination and mediastinal imaging (with
barium, gallium or CT scans) were only performed routinely when
they proved essential for judging tumour response.
Investigations and assessments were recorded on standard EORTC
clinical trial forms.
12.4 Design of Treatment
Human recombinant interferon alpha-2 (Schering Plough,
Kenilworth, NJ) was given on three days of each week at a dose
of 3MU subcutaneously. Cis-platinum (Bristol-Myers, Slough) was
2
given at lOOmg/m intravenously one week after the commencement
of the initial dose of IFN and thereafter at four weekly
intervals. Standard anti-emetic treatment (I.V. metoclopramide
infusion) was given with cis-platinum treatment.
The first assessment of response was therefore three weeks
after the second dose of CDDP. The minimum number of treatment
courses assigned for a full assessment of response to treatment
was two. Patients were only taken off chemotherapy under the
following circumstances: (i) unacceptable toxicity at any time,





















Table 12.1: Investigations performed during the study
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treatment (iii) complete regression of disease. Radiotherapy
was allowed at any time for the palliation of symptoms.
Patients were fully informed of the experimental nature of
the treatment and its potential benefits and side effects. They
were also informed of their right to withdraw from the protocol
therapy at any time if they wished. The study protocol was
approved by the local ethics committee. At the outset it was
anticipated that between 30-40 patients would be treated but
that patient accrual would be carefully reviewed. A minimum of
14 fully evaluable patients would be required before the study
could be closed.
12.5 Results
To date, 32 patients have been recruited into the study.
Their characteristics are summarised in table 12.2. As a group
of patients with inoperable NSCLC their mean age was
comparatively low (57.9 years). The distribution of
histological types of NSCLC was as usually encountered. The
majority of patients had a performance status of 1 on entry to
the study.
At the time of reporting of the 32 patients entered, 26 have
completed the study and 6 are still being treated. Of the 26
completed, 1 patient was not considered evaluable, leaving 25
completed evaluable patients. Four had a marked deterioration
in their condition due to progression of their disease prior to
receiving their first dose of CDDP. Since they did not receive
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Total number 32
Sex ratio (M:F) 7:1




Performance status on entry 0:9
1:20
2:3
* one patient in fact had incorrect histology (lymphoma)
Table 12.2: Characteristics of patients entered into study
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combinatior! therapy, these patients are not included in
evaluation of response to treatment. They have been included in
the analysis of results on an 'intention to treat' basis and are
considered elsewhere. The unevaluable patient was a 42 year old
man who had an abnormal chest radiograph and clear evidence of
bone metastases. The diagnosis of an adenocarcinoma was made on
a needle aspirate of his pulmonary lesion. The patient made a
dramatic response to the first course of treatment but
subsequently died in fulminant hepatic failure. At autopsy, his
pulmonary and bone lesions had completely regressed but his
liver was replaced by a large cell lymphoma. It was assumed
that lymphoma was the initial diagnosis (despite this unusual
differential response) and he was not deemed evaluable for the
study.
The toxicity recorded in 25 patients receiving at least one
course of CDDP is shown in table 12.3. Nausea and vomiting (WHO
grade 2-3) was seen in virtually all patients but only one
patient experienced grade 4 symptoms. In two patients this side
effect led to withdrawal from the study. 'Flu like symptoms
related to the IFN injections were common but only prevented one
patient from completing the study. Treatment delay (up to 1
week) due to a fall in creatinine clearance was necessary in
three patients. No significant myelosuppression was observed.
The majority of patients completing the study received two
courses of CDDP (Table 12.4). The four patients who only
received one course of CDDP had significant progressive disease
after this course. This table also shows the reasons for
withdrawal of patients from the protocol.
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Anaemia 5 (3 required transfusion)
Tinnitus 5
Diarrhoea 3




Dizziness after IFN 1
Peripheral neuropathy 1
Table 12.3: Toxicity seen in 23 patients receiving at least
one course of CDDP and IFN
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Still on study 6
TOTAL 32
Table 12.4: No of courses of CDDP received and reasons for
withdrawal of patients in study
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Age Histology Site of response Status
57 Squamous Chest Off study
61 Squamous Nodes Off study
61 Squamous Chest Off study
38 Adeno Nodes On study
51 Squamous Nodes On study
56 Squamous Chest On study
Table 12.5: Characteristics of responding patients
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Partial responses were seen in 6 male patients. 3 are still
being treated and 3 have been withdrawn due to significant
toxicity (Grade 3-4 nausea and vomiting, debilitating 'flu like
symptoms). The characteristics of these patients is shown in
table 12.5. Five of the six patients had squamous histology.
Half the patients had responses in neck nodes. They were not
significantly younger than the group of patients as a whole.
With 27 evaluable patients this represents a response rate of
22% with three patients still on treatment without evidence of
response as yet. The response rate on an 'intention to treat'
basis (i.e. including the four patients who were withdrawn
before receiving CDDP) is 19%. It is too early at this stage to
comment on survival figures for any groups of patients.
12.6 Discussion
This ongoing study has attempted to assess the potential of
combination therapy with CDDP and IFN in patients with NSCLC.
Low doses of IFN were given in a chronic schedule as this seemed
important in the xenograft studies which prompted the trial.
CDDP was administered at four weekly intervals rather than the
conventional three weekly, in an attempt to avoid any
enhancement of toxicity. Nausea and vomiting were seen in
virtually all patients but were appropriate to the amount of
CDDP given. Many patients experienced 'flu like symptoms from
IFN but these were rarely severe enough to limit treatment.
Toxicity from the combination was therefore predictable but
rarely dose limiting.
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Four patients were withdrawn from the study with progressive
disease between receiving their first dose of IFN and commencing
CDDP. All were elderly (aged 68-74) and had poorer performance
status (2 grade 1, 2 grade2) than the group as a whole. Clearly
the possibility that one week's treatment of IFN accelerated
their disease should be considered. No reports of this effect
have previously been recorded despite the fact that thousands of
patients with advanced cancers have been treated with IFNs.
Also these patients continued to deteriorate after the IFN was
discontinued. A more likely explanation of the findings is that
in retrospect these patients did not have a life expectancy of
12 weeks at entry and should not have been included in the
study. Although they did not receive combination therapy and
cannot be included in an analysis of response to this treatment,
they are included in the calculation of overall response rates
as it was our intention to treat them at the outset of the
trial.
Our toxicity data are very similar to those reported by
Walsh et al (1987) who performed a phase I study of the
combination of alpha IFN and CDDP in eighteen patients (6 with
NSCLC). They used a slightly higher dose of IFN (5 x 10^
2
units/m ) in an identical schedule with escalating doses of CDDP
2
up to 30mg/m given weekly.
Six partial responses have been seen so far. All but one
occurring in patients with squamous histology. This represents
a response rate of 22%. How does this compare with single agent
activity of CDDP in this type of patient? Five reports have
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been published on the activity of CDDP in NSCLC. Doses have
2
ranged from 75 to 120mg/m every three to six weeks. Response
rates have shown considerable variation and do not appear to
relate to dosage. The two largest studies (DeJager 1980, Vogel
1982) reported response rates of 25% and 32% respectively. The
response duration was around 3 months and median survival time 5
months for both trials. Three smaller studies (Britell 1978,
Casper 1979, Rossof 1976) reported response rates below 10%.
Survival data were not recorded for these studies. So although
no direct comparison can be made to a single agent study using
an identical dosage schedule, our results appear encouraging and
worthy of further study. The rational development of this
treatment would seem to be a randomised comparison between CDDP
and CDDP plus IFN in NSCLC patients.
Clinical responses were seen in both primary tumours and in
lymph node metastases. It is of interest that five of the six
responders to the treatment had squamous histology. This
phenomenon has not been seen in single agent studies of CDDP in
NSCLC where responses were seen evenly in adenocarcinoma and
squamous tumours. In reported studies few responses were seen
in large cell lesions (Souhami 1985). Potentiation of CDDP by
IFN was seen in both adenocarcinoma and squamous xenografts but
not in adenocarcinoma cell lines. The reason why patients with
squamous histology seemed to respond more readily to the
combination therefore remains unclear. A larger study is
required to determine whether certain tumour types are more
sensitive.
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CONCLUSIONS AND FUTURE DIRECTIONS
This thesis has investigated the potential of a new form of treatment
in human lung cancer. This tumour is a major killer of both men and women
throughout the world and is currently remarkably resistant to existing
therapies. Some progress has been made in the last two decades in
prolonging the survival of patients with small cell lung cancer using
combination chemotherapy. However, long term survival is uncommon. Non
small cell lung cancer, which is three times more common than SCLC does not
respond to standard chemotherapy. If effective, this would seem the
logical form of treatment since the vast majority of patients present with
widespread disease. Clearly newer agents and more effective regimes are
required if an impact on this condition is to be made.
The development of new anticancer agents has been facilitated by the
emergence of laboratory methods that allow for testing of cytotoxic
activity outwith the patient. Although no perfect system exists it is
possible to evaluate new treatments rapidly and to avoid unnecessary
toxicity to patients from the use of inactive regimes.
Interferons have burst onto the clinical scene in the last decade
without such rigorous pre-clinical testing. The results of phase II
clinical studies have been disappointing with significant activity only
demonstrated in certain haematological malignancies. Few responses have
been seen in the common cancers. Single agent studies in patients with
lung cancer were certainly negative and there is no place for this form of
treatment in these patients.
The concept of combining interferons with anti-cancer agents is not
new, the first report of the combinationin a laboratory model appearing in
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1974 (Chirigos). Recently much interest has been shown in this form of
treatment. Different workers using different laboratory test systems have
published results which have on the whole looked very encouraging. We were
the first to report on these interactions in human lung cancer.
The bulk of this thesis has described the interactions between IFN
alpha and cytotoxic agents in human lung cancer xenografts. In summary we
have shown promising interactions between a variety of agents and IFN in
NSCLC tumours but have been unable to produce similar results using the
same agents in SCLC xenografts. The reasons for this are unclear. However
in some aspects this is reassuring. If the increased activity was seen
with all drugs in all tumours then it would be likely that the effect was
due to some 'trick' of the system and not to a true interaction. The effect
seen is certainly more complex than this.
There is evidence from both animal and clinical studies to show that
the administration of larger doses of IFN results in greater inhibition of
tumour growth, presumably reflecting the direct cytotoxic action of IFN.
This does not seem to be the case for IFN/drug combinations. Despite the
fact that few studies investigating the effect of dose and schedule on
IFN/drug interactions have been performed, many clinical trials using this
form of treatment are ongoing. Most studies aopear to be using the maximum
tolerated dose of each agent which may not be optimal. It is important if
these studies are negative to investigate other doses and schedules of
promising combinations before concluding that no interaction occurs.
A major hurdle in designing relevant clinical studies in this field is
to be the lack of understanding concerning the possible mechanisms by which
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drugs may interact with interferons. The scope of this project did not
allow for detailed investigation of this problem. However it was shown
that the results obtained in the xenograft model were not mediated through
increased toxicity to the host animal. We have been unable to show that
the modulation of cell cycle distribution is a factor in drug/lFN
interactions and must conclude that other mechanisms are involved.
The results from the in vitro experiments described in this thesis are
disappointing. On no occasion was a significant synergistic interaction
seen. Technical problems prevented the direct in vitro/in vivo comparison
of a treatment regime which was promising in vivo but the one comparison
which was made showed similar results in each system. Other workers have
clearly demonstrated synergy in vitro and it must be concluded that these
interactions represent a direct action on tumour cells.
The results of our clinical study merit further investigation. The
toxicity from the combination was predictable and rarely dose limiting. The
high frequency of squamous histology in responding patients was unexpected
although it is interesting that in the xenograft studies NX002, a squamous
carcinoma, was the most sensitive tumour to the CDDP/IFN regime.
What are the possible future directions of this research? In the
laboratory it is important to continue assessing different test systems.
However, the possible permutations are virtually infinite and the purpose
of this kind of work now must be to look for the emergence of a oattern of
interactions. The main thrust of preclinical work in this field must now
involve the investigation of the possible mechanisms by which synergy can
occur.
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Clearly the systems used for these experiments should involve tumours
common to clinical practice and be capable of producing relevant responses.
Work should only be done using agents where there is no doubt that a
positive interaction occurs and using dosage regimes which could be
converted to a clinical setting. Although it may be technically easier to
use an in vitro model it may be more relevant in the final outcome to
involve an animal system despite the problems of species specificity.
Perhaps the most fruitful avenue of research to follow initially would
be to study the effect of IFNs on drug metabolism. Techniques are now
evolving to monitor drug kinetics and effects at the cellular and even
nuclear level and it would seem relevant to study drug metabolism with and
without the influence of IFNs where positive interactions are known to
occur. Such studies are currently ongoing in our laboratory. In the future
it is hoped that groups interested in IFN/drug interactions will
collaborate in this form of research rather than pursuing individual ideas
on models which do not show clear synergy.
Another possible fruitful area for research would be to increase the
understanding of IFN on host responses. Many earlier clinical studies have
shown that the same dose of IFN can cause quite different amounts of
stimulation of the immune system in different individuals. This may be
important when interpreting data from groups of patients given the same
dose of IFN in a clinical study. However at present it seems improbable
that these effects are important in IFN/drug interactions.
Further clinical studies are certainly needed to confirm that these
interactions are clinically important and not just an artefact of
laboratory tumour model systems. The best way to investigate this is to
perform a direct comparison of the activity of CDDP alone and with IFN in a
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group of patients with NSCLC. As discussed earlier, careful consideration
will have to be given to dosage regimes and schedules. If the addition of
IFN confers only marginal benefit then a large group of patients will have
to be recruited and the trial will take a long time to produce results.
However at the end of the day, this form of assessment has to be undertaken
to prove whether this interesting idea of combining IFN with cytotoxic
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Isobologram showing interaction between IFN and CDDP in A549
(Courtney Assay). The cross marks the observed effect with
IFN/CDDP combination. This would appear to be sub-additive.
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APPENDIX II
In vitro plastic assays
1. A549 (24 hour exposure)
% inhibition of colony formation
3














(IFN 10 units/ml as single agent caused 1% inhibition)
2. H125 (24 hour exposure)








CDDP dose CDDP alone
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10 units/ml as a single agent caused 20% inhibition)
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3. A549 (5 day exposure)
% inhibition of colony formation
3








0. 10 57 95
(IFN 10 units/ml as a single agent caused 67% inhibition)
